var title_f41_61_42960="Aortic regurgitation as heard at the apex";
var content_f41_61_42960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/56371/aorapex_conv.mp4?title=Aortic+regurgitation+as+heard+at+the+apex\" style=\"width:410px;height:474px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phonocardiogram of aortic regurgitation as heard at the apex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Carotid artery pulse tracing and phonocardiogram of aortic regurgitation as heard at the apex. There is a fourth heart sound (S4) heard prior to S1 (mitral and tricuspid valve closure) and the upstroke of the carotid arterial pulses. This is the result of atrial contraction into the \"stiffened\" left ventricle. Following S1 is a short systolic ejection murmur which results from the large stroke volume seen in aortic regurgitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_61_42960=[""].join("\n");
var outline_f41_61_42960=null;
var title_f41_61_42961="AML FAB M0";
var content_f41_61_42961=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute myeloid leukemia (AML FAB M0)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate from a patient with AML (FAB classification M0). (Wright-Giemsa stain). The blasts lack differentiating features and were nonreactive to Sudan Black B and myeloperoxidase staining. More than 20 percent of the blasts expressed myeloid antigens CD13 and CD33. The blasts were terminal transferase negative and nonreactive with antibodies to lymphocytes. Auer rods were not found.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_61_42961=[""].join("\n");
var outline_f41_61_42961=null;
var title_f41_61_42962="Flurbiprofen (ophthalmic): Pediatric drug information";
var content_f41_61_42962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flurbiprofen (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?22/29/22995?source=see_link\">",
"    see \"Flurbiprofen (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/3/38963?source=see_link\">",
"    see \"Flurbiprofen (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8101431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ocufen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10480644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10480754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/29/22995?source=see_link\">",
"      see \"Flurbiprofen (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Instill 1 drop every 30 minutes starting 2 hours prior to surgery (total of 4 drops to each affected eye)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8101561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as sodium [drops]: 0.03% (2.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocufen&reg;: 0.03% (2.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8101434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10480755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Instill drops into affected eye(s); avoid contact of container tip with skin or eye; apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic effects",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10480661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For inhibition of intraoperative trauma-induced miosis; the value of flurbiprofen for the prevention and management of postoperative ocular inflammation and postoperative cystoid macular edema remains to be determined",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8101426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flurbiprofen may be confused with fenoprofen",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ocufen&reg; may be confused with Ocuflox&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ocufen [U.S., Canada, and multiple international markets] may be confused with Ocupres brand name for timolol [India]; Ocupress brand name for dorzolamide [Brazil]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8101462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Ocular: Bleeding tendency increased in ocular tissue (in conjunction with ocular surgery), burning (transient), fibrosis, hyperemia, hyphemia, irritation, miosis, mydriasis, stinging (transient)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10480662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to flurbiprofen or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10480752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with known bleeding tendencies or those receiving anticoagulants. Wound healing time may be slowed or delayed.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10480668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An increased risk of bleeding in ocular tissues may occur in conjunction with ocular surgery. Use with caution in patients with sensitivity to acetylsalicylic acid or other nonsteroidal anti-inflammatory agents.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8101501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Latanoprost: NSAID (Ophthalmic) may diminish the therapeutic effect of Latanoprost.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8101454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8101455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed following systemic administration of flurbiprofen in animal reproduction studies; therefore, flurbiprofen ophthalmic is classified as pregnancy category C. Information related to systemic absorption following topical application of the eye drops has not been located. Systemic absorption would be required in order for flurbiprofen to cross the placenta and reach the fetus. Refer to the Flurbiprofen (Systemic) monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10480756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic eye exams",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10482784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10480757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/3/38963?source=see_link\">",
"      see \"Flurbiprofen (ophthalmic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic solution may cause mild burning or stinging; notify physician if this becomes severe or is persistent.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15991 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-CE19846B1C-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_61_42962=[""].join("\n");
var outline_f41_61_42962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101431\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10480644\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10480754\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101561\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101434\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10480755\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10480661\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101426\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101462\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10480662\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10480752\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10480668\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299357\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101501\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101454\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101455\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10480756\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482784\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10480757\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15991\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15991|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/29/22995?source=related_link\">",
"      Flurbiprofen (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/3/38963?source=related_link\">",
"      Flurbiprofen (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/19/30008?source=related_link\">",
"      Flurbiprofen (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/35/36405?source=related_link\">",
"      Flurbiprofen (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/46/7911?source=related_link\">",
"      Flurbiprofen (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_61_42963="Antipyrine and benzocaine: Patient drug information";
var content_f41_61_42963=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Antipyrine and benzocaine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/51/11060?source=see_link\">",
"     see \"Antipyrine and benzocaine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/11/14514?source=see_link\">",
"     see \"Antipyrine and benzocaine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15070561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aurodex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Auralgan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691610",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain, swelling, and pressure linked with some ear infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to soften earwax so it may be taken out.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701532",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to antipyrine, benzocaine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698033",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ear irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699025",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad ear irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the ear only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lie on your side with problem ear up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pull the outer ear outward and upward.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put drops in ear without touching dropper to ear. Stay on side for 2 minutes or put cotton plug in ear.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Throw away any part not used after 6 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12379 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-22FFA76FCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_61_42963=[""].join("\n");
var outline_f41_61_42963=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15070561\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135881\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019073\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019072\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019077\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019078\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019080\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019075\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019076\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019081\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019082\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/51/11060?source=related_link\">",
"      Antipyrine and benzocaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/11/14514?source=related_link\">",
"      Antipyrine and benzocaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_61_42964="Entropion";
var content_f41_61_42964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Entropion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inward turning of the lower eyelid with eyelashes rubbing against the ocular surface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_61_42964=[""].join("\n");
var outline_f41_61_42964=null;
var title_f41_61_42965="Nefazodone: Patient drug information";
var content_f41_61_42965=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nefazodone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/0/2057?source=see_link\">",
"     see \"Nefazodone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/7/1145?source=see_link\">",
"     see \"Nefazodone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat post-traumatic stress.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nefazodone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Liver disease or recent heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697176",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have tried to take your own life, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695854",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime if it causes sleepiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10895 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_61_42965=[""].join("\n");
var outline_f41_61_42965=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027902\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027904\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027903\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027908\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027909\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027911\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027906\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027907\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027912\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027913\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/0/2057?source=related_link\">",
"      Nefazodone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/7/1145?source=related_link\">",
"      Nefazodone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_61_42966="Cyclic neutropenia";
var content_f41_61_42966=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cyclic neutropenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/61/42966/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/61/42966/contributors\">",
"     Thomas D Coates, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/61/42966/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/61/42966/contributors\">",
"     Laurence A Boxer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/61/42966/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/61/42966/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/61/42966/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic review discusses cyclic neutropenia (also called cyclic hematopoiesis), which, in contrast to other rare congenital neutropenias, tends to be mild and benign, but can occasionally be severe.",
"   </p>",
"   <p>",
"    Other causes of neutropenia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24937?source=see_link\">",
"     \"Congenital neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DISEASE OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclic neutropenia is a rare, dominantly inherited disorder with variable expression and an estimated incidence of one to two per million [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is characterized by neutropenia that recurs every 14 to 35 days, although over 90 percent of patients exhibit a cycle period of 21 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/3\">",
"     3",
"    </a>",
"    ]. While the disease tends to be benign, several affected patients have died of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/4\">",
"     4",
"    </a>",
"    ]. Most of the patients present in the first year of life.",
"   </p>",
"   <p>",
"    There is an acquired adult onset form of cyclic neutropenia; however, it is autoimmune rather than genetic in nature and has been found in association with T cell large granular lymphocyte leukemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21018?source=see_link&amp;anchor=H458740684#H458740684\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclic neutropenia can be cured by hematopoietic cell transplantation in an animal model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/4\">",
"     4",
"    </a>",
"    ] and has been transferred from an affected human donor to a recipient following hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/5\">",
"     5",
"    </a>",
"    ], demonstrating that this disorder is an intrinsic disorder of bone marrow progenitor cells.",
"   </p>",
"   <p>",
"    The bone marrow in this disorder is usually hypocellular with an arrest in myelocyte maturation during times of neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ]. At the onset of the neutropenia, postmitotic cells are absent from the marrow, but earlier precursors are present. Microscopic studies during all phases of the cycle show cellular blebbing and nuclear condensation, typical of apoptosis. Flow cytometric studies have shown increased numbers of annexin-V labeled myeloid precursors, indicating selective apoptotic death, resulting in removal of neutrophil precursors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/8\">",
"     8",
"    </a>",
"    ]. Consistent with these observations, early mathematical models of hematopoiesis had predicted that oscillations in peripheral neutrophil counts would occur if there were an increased rate of irreversible cell loss within the stem cell pool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cyclic neutropenia has been attributed to mutations in the elastase gene (ELA2, now called ELANE) on chromosome 19p13.3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. The mutations occur in exon 4 or 5 or at the junction of exon 4 and intron 4. Mutations occur in only one allele of the ELANE gene, suggesting a gain-of-function or aberrant function mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/3,10,12\">",
"     3,10,12",
"    </a>",
"    ]. Mutations of ELANE in cyclic neutropenia are usually, but not always, different from those found in severe congenital neutropenia (SCN). Unlike SCN, cyclic neutropenia is not associated with malignant transformation to acute myeloid leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one subject with cyclic neutropenia, a double de novo mutation was found in the GFI1 gene, a transcriptional regulator of ELANE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclic neutropenia usually presents during the first year of life with recurring fevers and neutropenia. It can occur in a familial pattern suggesting autosomal dominant inheritance. Among families with autosomal dominant disease, there is a wide spectrum of disease severity, ranging from an asymptomatic state to life-threatening infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/16\">",
"     16",
"    </a>",
"    ]. Many parents will state that the affected child does not feel well for two or three days out of the month, whether or not there is actual fever.",
"   </p>",
"   <p>",
"    The hallmark of the clinical presentation is the very predictable recurrence of symptoms. The period is 14 to 35 days in various individuals but is usually consistent with each patient, most often at about 21 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/3\">",
"     3",
"    </a>",
"    ]. Associated recurrent fever, pharyngitis, gingivitis, stomatitis, and bacterial infections are observed in most patients. During periods of severe neutropenia, which typically last one week during each cycle, the patients are prone to malaise, fever, aphthous stomatitis, and occasionally serious cutaneous and subcutaneous infections. The duration of neutropenia is quite variable between patients but is consistent for an individual. The cycling seems to decrease with age and can disappear by age 30 in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/9,16\">",
"     9,16",
"    </a>",
"    ]. The severity of the infections parallels the severity of the neutropenia and can be variable. While the disease tends to be benign, a number of patients have died of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with other primary neutropenias, examination of the gingiva and oral mucosa is very helpful. In contrast to patients with neutropenia and normal marrow reserve pools, patients with neutropenia due to decreased production, such as cyclic neutropenia, are not able to mobilize neutrophils to sites of infection and develop chronic mouth ulcers and gingival disease. Thus, the presence of significant gingival disease suggests more significant duration of neutropenia.",
"   </p>",
"   <p>",
"    Gingival inflammation, edema, and recession can occur; alveolar bone support may be lost in the preschool-age child, resulting in premature tooth mobility and loss (",
"    <a class=\"graphic graphic_picture graphicRef79500 \" href=\"mobipreview.htm?2/40/2689\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/60/8137?source=see_link&amp;anchor=H8#H8\">",
"     \"Systemic conditions associated with periodontal disease in children\", section on 'Cyclic neutropenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The symptoms of cyclic neutropenia are not from the neutropenia itself but from the inflammatory consequences of infection due to neutropenia. As such, the symptoms, if they occur, lag behind the neutropenia, such that neutrophil counts are usually about to recover when the child starts to feel ill. Interestingly, patients may report an increased sense of well-being as their absolute neutrophil counts recover to",
"    <span class=\"nowrap\">",
"     &gt;500/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One particularly severe infection that occurs in these patients is Clostridium septicum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. Myonecrosis from this organism in the adult is usually due to bacteremia secondary to a lesion in the gastrointestinal tract, often a colonic malignancy. In children, on the other hand, infection with this organism is almost always due to neutropenia. As an example, in one review of children with Clostridium septicum infection not due to trauma, neutropenia was due to chemotherapy in 70 percent and cyclic neutropenia in 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/18\">",
"     18",
"    </a>",
"    ]. The presence of abdominal discomfort, pain or tenderness, especially during the neutropenic phase of the cycle, should not be ignored. Several of the reported deaths in patients with cyclic neutropenia were after an acute illness with abdominal pain and were associated with Clostridia or gram negative organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12264?source=see_link\">",
"     \"Clostridial myonecrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cyclic neutropenia is usually not associated with short stature, dysmorphic features, chronic diarrhea, or hepatosplenomegaly. These features suggest presence of some disorder other than cyclic neutropenia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24937?source=see_link&amp;anchor=H430729003#H430729003\">",
"     \"Congenital neutropenia\", section on 'Shwachman-Diamond Syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Childhood cyclic neutropenia can persist for many years, but tends to decrease in severity with time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/9,16\">",
"     9,16",
"    </a>",
"    ]. Most affected children survive to adulthood; symptoms are often milder after the onset of puberty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclic neutropenia is an exceedingly rare cause of neutropenia; the diagnosis should not be entertained in the absence of the clinical picture noted above. Cyclic neutropenia must be differentiated from cyclic fevers without neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/19\">",
"     19",
"    </a>",
"    ] and from other causes of neutropenia. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The diagnosis of cyclic neutropenia is established by documentation of an absolute neutrophil count",
"    <span class=\"nowrap\">",
"     &lt;200/microL",
"    </span>",
"    on at least three to five consecutive days per cycle of each of three regularly spaced cycles. This typically requires monitoring of the neutrophil count two to three times per week for six to eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/2,3,16\">",
"     2,3,16",
"    </a>",
"    ]. The nadir of the neutropenia can be missed if the patient is monitored less frequently. The cycling phenomenon can occur intermittently in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/16\">",
"     16",
"    </a>",
"    ], making the diagnosis more difficult. Of note, the monocyte counts cycle out of phase with the neutrophils with significant monocytosis at the nadir of the neutrophil counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/16\">",
"     16",
"    </a>",
"    ]. The presence of monocytosis can be seen in other types of congenital neutropenia as well, but is not common in benign neutropenia. Testing for the ELANE gene mutation can be helpful and should be done in all cases where the index of suspicion is high.",
"   </p>",
"   <p>",
"    In most patients with cyclic neutropenia, blood neutrophil counts oscillate between mild and severe neutropenia, with ANCs of",
"    <span class=\"nowrap\">",
"     100/microL",
"    </span>",
"    for three to six days with every cycle. Although monocytes, eosinophils, lymphocytes, platelets, and reticulocytes also oscillate with the same period as the neutrophils, their oscillations are generally around normal mean values. There is usually a reciprocal monocytosis during the period of neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/9,16\">",
"     9,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone marrow aspiration is not helpful for making a diagnosis in patients suspected of having cyclic neutropenia.",
"   </p>",
"   <p>",
"    DNA mutational analysis for the ELANE gene is positive in 90 to 100 percent of patients with cyclic neutropenia and can be helpful in confirming the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/2,20\">",
"     2,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the name of the syndrome is known by most physicians and is often found at the top of the differential diagnosis whenever neutropenia is seen, the diagnosis of true cyclic neutropenia is rarely confirmed.",
"   </p>",
"   <p>",
"    It is not uncommon to see patients whose neutrophil counts cycle with nadirs in the 500 to",
"    <span class=\"nowrap\">",
"     1000/microL",
"    </span>",
"    range. These patients usually have chronic benign (idiopathic) neutropenia. They usually do not have any symptoms, nor do they have the signs of chronic gingival infection characteristic of patients with chronic severe neutropenia and do not meet the criteria for the diagnosis of chronic severe neutropenia or cyclic neutropenia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42520?source=see_link&amp;anchor=H9#H9\">",
"     \"Immune neutropenia\", section on 'Chronic idiopathic neutropenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cyclic episodes of fever due to cyclic neutropenia must be differentiated from the periodic fever syndromes (eg, familial Mediterranean fever, TNF receptor-1 associated periodic syndrome, hyper-IgD syndrome), disorders that are not associated with neutropenia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15494?source=see_link&amp;anchor=H2#H2\">",
"     \"Periodic fever syndromes and other autoinflammatory diseases: An overview\", section on 'The periodic fever syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Shwachman syndrome, lymphoproliferative disorders of large granular lymphocytes (LDGL) and primary immunodeficiencies can also present with a cyclic pattern, and should be included in the differential if cyclic neutropenia, dysmorphic features, or hepatosplenomegaly are present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24937?source=see_link\">",
"     \"Congenital neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cyclic neutropenia often have, or will develop, severe dental, gingival, and mucosal infection. In general, patients with cyclic neutropenia are not at the same high risk for infection as post-chemotherapy patients, since they have active monocytosis during neutropenia and their lymphocyte-mediated immunity is not impaired. As a result, routine hospitalization for their episodes of febrile neutropenia is usually not required.",
"   </p>",
"   <p>",
"    However, infectious deaths have been reported in patients with cyclic neutropenia. Accordingly, these patients should not be assumed to be normal. They should be evaluated by a physician familiar with the disorder when they have significant fever during episodes of neutropenia. The presence of abdominal pain, tenderness, or vomiting associated with neutropenia raises the possibility of neutropenic ileocolitis, which requires treatment with parenteral antibiotics to cover enteric organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/3,16\">",
"     3,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend treating all patients with confirmed cyclic neutropenia with recombinant G-CSF (see below). This will reduce gingival and dental complications and reduce the risk of sepsis during periods of severe neutropenia. As the neutrophil cycling can stop and be replaced by a mild chronic neutropenia in third decade of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/16\">",
"     16",
"    </a>",
"    ], continued use of G-CSF may not be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of such children with cyclic neutropenia is largely supportive and should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regular and aggressive dental care is recommended. The antibacterial mouthwash Peridex&reg; is useful in decreasing gingivitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/17,21-23\">",
"       17,21-23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clinical judgment is required with respect to aggressive antibacterial therapy in febrile patients. Unfortunately, no absolute guidelines concerning antibiotic use can be given. An experienced clinician familiar with the patient and the disorder can avoid unnecessary treatment and yet prevent disastrous consequences from occasional septic episodes.",
"     </li>",
"     <li>",
"      Bone density should be monitored for development of osteoporosis during prolonged treatment with G-CSF, as osteoporosis is a known side effect of this medication. Appropriate treatment should be provided, if this complication is present. We would also recommend monitoring of 25-OH-vitamin D levels and appropriate supplementation to maintain adequate levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Granulocyte colony-stimulating factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) to patients with cyclic neutropenia and recurrent severe infections leads to an increase in the mean value of the absolute neutrophil count by as much as 10- to 20-fold and prevents infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/22,24-27\">",
"     22,24-27",
"    </a>",
"    ]. In an initial report, six patients with cyclic neutropenia were treated with recombinant human G-CSF for 3 to 15 months at doses ranging from 3 to 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/22\">",
"     22",
"    </a>",
"    ]. The following benefits were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median absolute neutrophil count (ANC) increased from 700 to",
"      <span class=\"nowrap\">",
"       9800/microL.",
"      </span>",
"      There were no elevations in the average counts of other cells.",
"     </li>",
"     <li>",
"      Cycling of blood counts continued in five of the patients, but the duration of cycles decreased from 21 to 14 days. In the remaining patient with adult-onset disease, the increase in ANC was associated with disappearance of the cyclic fluctuations.",
"     </li>",
"     <li>",
"      The number of days of severe neutropenia (ANC",
"      <span class=\"nowrap\">",
"       &lt;200/microL)",
"      </span>",
"      was reduced from a mean of 13 to less than one day per month and the nadir counts were higher.",
"     </li>",
"     <li>",
"      Therapy reduced the frequency of episodes of oropharyngeal inflammation, fever, and infections, demonstrating that treatment with rhG-CSF is effective management for such patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients respond to subcutaneous doses of G-CSF in the range of 2 to 3",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    every one to two days throughout the cycle, and do not usually require the higher doses often needed in severe congenital neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/24/12680?source=see_link&amp;anchor=H10#H10\">",
"     \"Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes\", section on 'Cyclic neutropenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following treatment with G-CSF the amplitude of the oscillations in the neutrophil count is increased and the period of the oscillations is reduced to approximately 14 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/9\">",
"     9",
"    </a>",
"    ]. These oscillations in the neutrophil count make it difficult to dose G-CSF, as the neutrophil count obviously depends on when during the cycle testing is done. The same G-CSF dose management approach used for patients on chemotherapy cannot be used because of the oscillating counts.",
"   </p>",
"   <p>",
"    We find monitoring of the erythrocyte sedimentation rate (ESR) to be very helpful. If the ESR is normal, the average ANC is likely to be adequate. Clinical assessment for gingival disease is also important. If the ANC is usually adequate, the gingiva will be normal appearing. If the nadir of the ANC is consistently above 500 to",
"    <span class=\"nowrap\">",
"     800/microL,",
"    </span>",
"    the patients will likely not develop symptoms and will be protected from septic complications.",
"   </p>",
"   <p>",
"    In a long-term study, 10 patients were treated with subcutaneous G-CSF (1 to 3",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day) for four to six years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/24\">",
"     24",
"    </a>",
"    ]. Neutrophil oscillation persisted, but the cycle length was reduced to about 14 days and the duration of neutropenic periods was shortened to less than two days per cycle. None of the patients required intravenous antibiotics during G-CSF treatment. A study in one patient has suggested that an alternate day or three days per week treatment regimen is effective and results in major cost savings compared with daily therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is variability in clinical symptoms and, largely because of the rarity of the disorder, no clear data regarding treatment with G-CSF. We would recommend treating all children with G-CSF with the intent of keeping the nadir of the ANC",
"    <span class=\"nowrap\">",
"     &gt;500/microL.",
"    </span>",
"    G-CSF can be stopped in some patients as they get into their late teens and twenties, as the neutropenia usually lessens spontaneously. However, each case has to be evaluated individually and no clear age-related guideline can be given.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/28/12741?source=see_link\">",
"     Pegfilgrastim",
"    </a>",
"    , a long-acting preparation of G-CSF, has been used in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/23\">",
"     23",
"    </a>",
"    ]. However, it is expensive and difficult to dose appropriately in young children.",
"   </p>",
"   <p>",
"    Treatment with recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) has not been as successful as treatment with G-CSF. In one comparative study in three children with cyclic neutropenia, oscillations in the ANC were dampened but there were only modest increases in the ANC (1.6- to 3.9-fold following GM-CSF versus more than 20-fold with G-CSF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADULT ONSET DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult onset cyclic neutropenia is an autoimmune disorder related to the presence of cytotoxic lymphocytes. The adult form has been associated with a clonal proliferation of CD56+ large granular lymphocytes. The mainstay of therapy is immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21018?source=see_link&amp;anchor=H458740684#H458740684\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclic neutropenia is a rare, dominantly inherited disorder of bone marrow progenitor cells, characterized by recurrent neutropenia, with a cycle period of about 21 days. It has been attributed to mutations in the elastase gene (ELANE, formerly called ELA2) on chromosome 19p13.3. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Disease overview'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Symptoms",
"      </strong>",
"      &mdash; Symptoms usually begin during the first year of life and consist of recurrent fever, pharyngitis, gingivitis, stomatitis, and bacterial infections. Affected patients are prone to malaise, fever, aphthous stomatitis, and occasionally serious cutaneous and subcutaneous infections. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Diagnosis",
"      </strong>",
"      &mdash; The diagnosis of cyclic neutropenia is established by documentation of an absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &lt;200/microL",
"      </span>",
"      on at least three to five consecutive days per cycle of each of three regularly spaced cycles and a nadir",
"      <span class=\"nowrap\">",
"       &lt;200/microL.",
"      </span>",
"      This requires measurement of the ANC at least twice a week for a minimum of six and preferably eight consecutive weeks. The absolute neutrophil count in general should not be above",
"      <span class=\"nowrap\">",
"       2000/microL",
"      </span>",
"      at other times [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/61/42966/abstract/16\">",
"       16",
"      </a>",
"      ]. DNA mutational analysis for the ELANE gene is positive in 90 to 100 percent of patients with cyclic neutropenia, and can be helpful in confirming the diagnosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Differential diagnosis",
"      </strong>",
"      &mdash; The differential diagnosis of cyclic neutropenia includes the various causes of periodic fever and well as the various causes of severe neutropenia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15494?source=see_link&amp;anchor=H2#H2\">",
"       \"Periodic fever syndromes and other autoinflammatory diseases: An overview\", section on 'The periodic fever syndromes'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18170?source=see_link\">",
"       \"Overview of neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Treatment",
"      </strong>",
"      &mdash; We recommend treatment of all children with confirmed cyclic neutropenia with recombinant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF). Specifically, patients with recurrent symptoms, evidence of gingival disease, or severe infection, should receive G-CSF and the dose adjusted to keep the nadir of the ANC",
"      <span class=\"nowrap\">",
"       &gt;200/microL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Granulocyte colony-stimulating factor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Supportive care",
"      </strong>",
"      &mdash;",
"      <strong>",
"      </strong>",
"      Supportive care includes regular and aggressive dental care, monitoring for osteoporosis and genetic counseling. Aggressive antibacterial therapy may be required in patients who are febrile during periods of neutropenia, especially if there are associated gastrointestinal symptoms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/3/20537?source=see_link&amp;anchor=H9#H9\">",
"       \"Evaluation and management of fever in children with non-chemotherapy-induced neutropenia\", section on 'Empiric antibiotics'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H8\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/1\">",
"      Bellann&eacute;-Chantelot C, Clauin S, Leblanc T, et al. Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. Blood 2004; 103:4119.",
"     </a>",
"    </li>",
"    <li>",
"     Dale DC. ELANE-related neutropenia. In: GeneReviews, Pagon RA, Dolan CR, Stephens K (Eds), University of Washington, Seattle 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/3\">",
"      Dale DC, Bolyard AA, Aprikyan A. Cyclic neutropenia. Semin Hematol 2002; 39:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/4\">",
"      Lange RD, Jones JB. Cyclic neutropenia. Review of clinical manifestations and management. Am J Pediatr Hematol Oncol 1981; 3:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/5\">",
"      Krance RA, Spruce WE, Forman SJ, et al. Human cyclic neutropenia transferred by allogeneic bone marrow grafting. Blood 1982; 60:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/6\">",
"      Leale M. Recurrent furunculosis in an infant showing unusual blood picture. JAMA 1910; 54:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/7\">",
"      Rutledge B, Hansen-Pruss O, Thayer W. Recurrent agranulocytosis. Bull Johns Hopkins Hosp 1930; 46:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/8\">",
"      Aprikyan AA, Liles WC, Rodger E, et al. Impaired survival of bone marrow hematopoietic progenitor cells in cyclic neutropenia. Blood 2001; 97:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/9\">",
"      Haurie C, Dale DC, Mackey MC. Cyclical neutropenia and other periodic hematological disorders: a review of mechanisms and mathematical models. Blood 1998; 92:2629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/10\">",
"      Aprikyan AA, Dale DC. Mutations in the neutrophil elastase gene in cyclic and congenital neutropenia. Curr Opin Immunol 2001; 13:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/11\">",
"      Horwitz M, Benson KF, Duan Z, et al. Role of neutrophil elastase in bone marrow failure syndromes: molecular genetic revival of the chalone hypothesis. Curr Opin Hematol 2003; 10:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/12\">",
"      Dale DC, Person RE, Bolyard AA, et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood 2000; 96:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/13\">",
"      Horwitz M, Benson KF, Person RE, et al. Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis. Nat Genet 1999; 23:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/14\">",
"      Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006; 107:4628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/15\">",
"      Armistead PM, Wieder E, Akande O, et al. Cyclic neutropenia associated with T cell immunity to granulocyte proteases and a double de novo mutation in GFI1, a transcriptional regulator of ELANE. Br J Haematol 2010; 150:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/16\">",
"      Palmer SE, Stephens K, Dale DC. Genetics, phenotype, and natural history of autosomal dominant cyclic hematopoiesis. Am J Med Genet 1996; 66:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/17\">",
"      Sievers EL, Dale DC. Non-malignant neutropenia. Blood Rev 1996; 10:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/18\">",
"      Bar-Joseph G, Halberthal M, Sweed Y, et al. Clostridium septicum infection in children with cyclic neutropenia. J Pediatr 1997; 131:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/19\">",
"      Marshall GS, Edwards KM, Butler J, Lawton AR. Syndrome of periodic fever, pharyngitis, and aphthous stomatitis. J Pediatr 1987; 110:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/20\">",
"      Horwitz MS, Duan Z, Korkmaz B, et al. Neutrophil elastase in cyclic and severe congenital neutropenia. Blood 2007; 109:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/21\">",
"      Welte K, Boxer LA. Severe chronic neutropenia: pathophysiology and therapy. Semin Hematol 1997; 34:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/22\">",
"      Hammond WP 4th, Price TH, Souza LM, Dale DC. Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. N Engl J Med 1989; 320:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/23\">",
"      Matarasso S, Daniele V, Iorio Siciliano V, et al. The effect of recombinant granulocyte colony-stimulating factor on oral and periodontal manifestations in a patient with cyclic neutropenia: a case report. Int J Dent 2009; 2009:654239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/24\">",
"      Bonilla MA, Dale D, Zeidler C, et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol 1994; 88:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/25\">",
"      Heussner P, Haase D, Kanz L, et al. G-CSF in the long-term treatment of cyclic neutropenia and chronic idiopathic neutropenia in adult patients. Int J Hematol 1995; 62:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/26\">",
"      Dale DC, Bolyard AA, Hammond WP. Cyclic neutropenia: natural history and effects of long-term treatment with recombinant human granulocyte colony-stimulating factor. Cancer Invest 1993; 11:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/27\">",
"      Wright DG, Kenney RF, Oette DH, et al. Contrasting effects of recombinant human granulocyte-macrophage colony-stimulating factor (CSF) and granulocyte CSF treatment on the cycling of blood elements in childhood-onset cyclic neutropenia. Blood 1994; 84:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42966/abstract/28\">",
"      Jayabose S, Tugal O, Sandoval C, Li K. Recombinant human granulocyte colony stimulating factor in cyclic neutropenia: use of a new 3-day-a-week regimen. Am J Pediatr Hematol Oncol 1994; 16:338.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8370 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_61_42966=[""].join("\n");
var outline_f41_61_42966=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DISEASE OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Granulocyte colony-stimulating factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADULT ONSET DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8370\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8370|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/40/2689\" title=\"picture 1\">",
"      Cyclic neutropenia periodontal disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21018?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12264?source=related_link\">",
"      Clostridial myonecrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/3/20537?source=related_link\">",
"      Evaluation and management of fever in children with non-chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42520?source=related_link\">",
"      Immune neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/24/12680?source=related_link\">",
"      Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/60/8137?source=related_link\">",
"      Systemic conditions associated with periodontal disease in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_61_42967="Fast food for children and adolescents";
var content_f41_61_42967=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fast food for children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/61/42967/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/61/42967/contributors\">",
"     Debby Demory-Luce, PhD, RD, LD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/61/42967/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/61/42967/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/61/42967/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/61/42967/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/61/42967/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/61/42967/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/61/42967/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fast food restaurants or quick-service establishments are often the overall choice for food away from home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Socioeconomic trends, such as longer work hours, more women employed outside the home, and a high number of single-parent households have changed the way families obtain their meals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. As parents experience busier lifestyles, they demand convenience for their family meals. The consumption of fast food is fostered because of the quick service, convenience, good taste, and inexpensive prices relative to more traditional home-style restaurants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The National Restaurant Association estimates that the average American eats out an average of four times a week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/10\">",
"     10",
"    </a>",
"    ]. About 33 percent of children and adolescents in the United States consume fast food on a typical day, and intake increases with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. It is estimated that adolescents visit fast food restaurants approximately twice a week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/24/16778?source=see_link\">",
"     \"Adolescent eating habits\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, more than 49 percent of today's food dollar is spent away from home, and this value continues to rise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Driven by consumers' growing need for convenience, sales at quick-service restaurants were expected to generate $168 billion in 2011; a 3 percent gain over 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/16\">",
"     16",
"    </a>",
"    ]. Snack, convenience, fast foods, and sweets continue to dominate food advertisements viewed by children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/17\">",
"     17",
"    </a>",
"    ]. The marketing of these items contributes to the fast food consumption of US children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. On a typical day, preschool-aged children (2 to 5 years) view three television fast food advertisements, elementary-school children (6 to 11 years) view four television fast food advertisements, and adolescents (12 to 18 years) view five fast food television advertisements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/13\">",
"     13",
"    </a>",
"    ]. One study indicates that 98 percent of television food-product advertisements viewed by adolescents promote foods that are high in fat, sugar, or sodium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/21\">",
"     21",
"    </a>",
"    ]. In the United States, $8 billion is spent on food and beverages by children between the ages of 4 and 12 years, and these children also exert a strong influence on their parents' choices of quick-service establishments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Frequent consumption of fast food has adverse effects on nutrition because of excessive content of energy and fat and low nutritional value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Moreover, consumption of fast food is associated with other poor nutritional habits: surveys show that parents who reported purchasing fast food for family meals at least three times per week were significantly more likely than parents who reported purchasing fewer than three fast food family meals to report the availability of soft drinks and chips in the home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fast foods are a way of life for many American families, and eliminating fast foods may not be realistic. The challenge is to teach children and adolescents to make wise food choices when visiting fast food establishments. This is an important issue since the establishment of healthy eating patterns in childhood is linked to a reduction in chronic diseases, such as obesity, coronary heart disease, hypertension, type 2 diabetes, osteoporosis, and diet-related cancers later in life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/26-31\">",
"     26-31",
"    </a>",
"    ]. Healthful eating patterns for children over the age of two can be achieved by consumption of a prudent diet that is moderate in total fat, saturated fatty acids, and cholesterol, and high in complex carbohydrates, fiber, calcium, and antioxidant nutrients such as vitamins C and E and the carotenoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another useful strategy for improving young children's eating behaviors is to use marketing techniques for \"branding\" higher quality foods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/35\">",
"     35",
"    </a>",
"    ]. Children prefer the taste of foods and drinks if they think the selections are from well-known commercial establishments such as McDonald's; using marketing techniques to similarly \"brand\" higher quality foods may counterbalance some of the effects of fast food marketing. Educational strategies are sometimes effective in promoting healthy eating behaviors. As an example, the popularized film \"Super Size Me\" has the potential to educate and change behaviors including reducing fast food intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NUTRITIONAL CONSIDERATIONS OF FAST FOODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Junk food\" is a descriptive term commonly associated with fast food. Although \"junk food\" has negative connotation, not all foods found in fast food restaurants contribute to adverse dietary lifestyles and eating habits. The extent to which fast foods influence the nutritional status of the child or adolescent depends upon several factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The nutritive quality of the menu items",
"     </li>",
"     <li>",
"      The choice of menu items that comprise a meal",
"     </li>",
"     <li>",
"      The amounts consumed",
"     </li>",
"     <li>",
"      The frequency with which the meals are eaten",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Concerns",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Nutrient content",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many fast foods can be high in energy, total and saturated fat, added sugar, cholesterol, and sodium; and low in vitamins A and C,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    , fiber, and calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/24,39-42\">",
"     24,39-42",
"    </a>",
"    ]. This nutrient profile is evident in traditional fast food meals such as a hamburger, french fries, fruit turnover, and soft drink; or fried chicken, mashed potatoes with gravy, biscuit, and soft drink, as shown in menus 1 and 2 (",
"    <a class=\"graphic graphic_table graphicRef62971 \" href=\"mobipreview.htm?25/9/25757\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/43\">",
"     43",
"    </a>",
"    ]. Fat accounts for 45 to 55 percent of calories in some fast foods (as compared with recommended fat content of 30 percent or less of total calories). In a survey of fast food purchased at lunchtime from chain retailers in New York, only one in 36 meals purchased met the U.S. Food and Drug administration's guidelines for \"healthy\" sodium levels (600",
"    <span class=\"nowrap\">",
"     mg/meal),",
"    </span>",
"    and one in five meals exceeded the recommended daily limit for sodium (2300 mg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/44\">",
"     44",
"    </a>",
"    ]. The average meal purchased contained 880 calories and 1750 mg sodium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Portion size",
"    </span>",
"    &nbsp;&mdash;&nbsp;In response to health authorities' call to reduce portion sizes, fast food outlets have changed the names for portion sizes for menu items and meals. For example, major fast food outlets have phased out \"super-sized,\" \"biggie-sized,\" and \"jumbo-sized\" items; food items and meals are now available in \"small,\" \"medium,\" and \"large.\" However, at point of ordering, customers are encouraged to upgrade smaller menu items to larger sizes for a few cents more. Because of these marketing techniques, children and adolescents learn to equate \"volume\" with \"value\". In addition, most fast food outlets have \"specialty burgers\" available with one to four beef patties and additional bacon and cheese \"extras.\" Energy, fat, and sodium consumption increases substantially with the number of \"extras.\" The choice of \"large-size\" or \"specialty burgers\" can significantly increase the energy, fat, and sodium content of the meal. As an example, a large hamburger supplies 520 kcal and 29 g of fat compared with 250 kcal and 9 g of fat in a regular hamburger (",
"    <a class=\"graphic graphic_table graphicRef62971 \" href=\"mobipreview.htm?25/9/25757\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/43\">",
"     43",
"    </a>",
"    ]. Similarly, a large-size order of french fries and soft drink can add up to an additional 1070 kcal. Such a meal can provide 1610 kcal and 67 g of fat, which is 81 percent of daily energy needs and 100 percent of daily fat needs for a 10-year-old child, as shown in menu 3 (",
"    <a class=\"graphic graphic_table graphicRef62971 \" href=\"mobipreview.htm?25/9/25757\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Thus, the high energy density of a fast food meal tends to encourage over-consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/24,42\">",
"     24,42",
"    </a>",
"    ]. Legislation to require labeling on menus describing calorie content at the point of purchase is in place in several states, and national legislation is in progress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Customers who purchase fast food exhibit somewhat more restraint when the energy content is revealed. In a survey study of several fast food chains, customers purchased a mean of 827 calories per meal, and 34 percent purchased more than 1000 calories per meal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/48\">",
"     48",
"    </a>",
"    ]. When calorie information was posted at the point of purchase at one fast food outlet, patrons who noticed the information purchased an average of 52 fewer calories than those who did not notice the information. Similarly, in another study, 106 adolescents were asked to order dinner from fast food menus and then order from fast food menus with calorie and fat information posted next to the menu items. Although the majority (70 percent) of the adolescents did not modify their food-ordering behavior, 30 percent reduced calorie-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fat-ordering behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/49\">",
"     49",
"    </a>",
"    ]. Parents of young children also tend to respond to nutritional information if it is provided on the menu. In a randomized trial, the energy content of the food ordered by parents for their three to six year-old children was reduced by an average of 100 kcals when nutrition information was provided on the menu [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The social context of most fast food meals also encourages over-consumption: many fast food meals are consumed while riding in the car or watching television. In this type of setting children tend to overeat because their attention is distracted and they are less aware of satiety signals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4147846\">",
"    <span class=\"h3\">",
"     Data on nutritional effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings from a national household survey among children highlight the nutritional effects of fast food consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/11\">",
"     11",
"    </a>",
"    ]. Compared to children who did not eat fast food on a given day, children who did consumed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      More total energy (2236 versus 2049",
"      <span class=\"nowrap\">",
"       kcal/day)",
"      </span>",
"     </li>",
"     <li>",
"      More total fat (84 versus 75",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"     </li>",
"     <li>",
"      More total carbohydrates (303 versus 277",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"     </li>",
"     <li>",
"      More added sugars (122 versus 94",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"     </li>",
"     <li>",
"      More sugar-sweetened carbonated beverages (471 versus 243",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"     </li>",
"     <li>",
"      Less milk (236 versus 302",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"     </li>",
"     <li>",
"      Less fiber (13.2 versus 14.3",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"     </li>",
"     <li>",
"      Fewer fruits and non-starchy vegetables (103 versus 148",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in a longitudinal multicenter cohort study of female adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/39\">",
"     39",
"    </a>",
"    ]. In this study, increased frequency of fast food consumption was associated with increased intake of energy and sodium and increased intake of total fat and saturated fat as a percentage of calories.",
"   </p>",
"   <p>",
"    In a national study of adolescents, intake of milk, fruits and vegetables were generally low, and achievement of recommended intake was less likely in youth who consumed fast food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/23\">",
"     23",
"    </a>",
"    ]. No relationships were seen between fast food consumption and achievement of recommendations for grains,",
"    <span class=\"nowrap\">",
"     meats/beans,",
"    </span>",
"    and oils. In this study, no association was seen between adolescents' weight status and level of fast food intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4147871\">",
"    <span class=\"h3\">",
"     Association with obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fast food consumption may be particularly problematic for overweight adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/52\">",
"     52",
"    </a>",
"    ]. In one study of fast food consumption among lean (BMI &le;85th percentile for age and sex) and overweight (BMI &gt;85th percentile but &lt;98th percentile) adolescents, both groups were instructed to eat as much or as little as desired during a one-hour \"extra-large\" fast food meal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/53\">",
"     53",
"    </a>",
"    ]. In this setting, both groups ingested a large amount of energy (mean energy intake 1652 kcal or 62 percent of estimated daily requirement). However, overweight adolescents consumed more energy (1860 versus 1458 kcal, or 66.5 versus 57 percent of estimated daily requirement). In addition, whereas lean adolescents had similar total energy intakes on days during which they did and did not consume fast food (2575 versus 2622 kcal), overweight adolescents had increased total energy intake on fast food days (2703 versus 2295).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Opportunities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fortunately, choices at fast food restaurants are no longer limited to hamburgers, french fries, and soft drinks. Many of these establishments have modified their menus by offering lower-fat items in addition to traditional selections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. As a result, it is possible to order a healthier meal that provides a good supply of nutrients that children and adolescents need for growth and development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition to containing less fat, the following foods provide nutrients that are present in relatively low amounts in traditional fast food meals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Baked potato &mdash; vitamin C and fiber",
"     </li>",
"     <li>",
"      Vegetables (raw and cooked) &mdash; vitamins A and C and fiber",
"     </li>",
"     <li>",
"      Side salads and salad bars &mdash; vitamins A and C and fiber",
"     </li>",
"     <li>",
"      Fresh fruit &mdash; vitamins A and C and fiber",
"     </li>",
"     <li>",
"      Whole wheat buns &mdash; B vitamins and fiber",
"     </li>",
"     <li>",
"      Grilled chicken and lean red meats &mdash; iron and zinc",
"     </li>",
"     <li>",
"      Chili &mdash; fiber, zinc,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/31/22005?source=see_link\">",
"       folic acid",
"      </a>",
"      , and iron",
"     </li>",
"     <li>",
"      Low-fat frozen yogurt, yogurt shakes, and low-fat milk &mdash; calcium",
"     </li>",
"     <li>",
"      Orange juice &mdash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/31/22005?source=see_link\">",
"       folic acid",
"      </a>",
"      and vitamin C",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By selecting foods that are naturally nutrient dense (lower in fat content and higher in vitamins, minerals, and fiber) and a cooking method that does not add a large amount of fat, well-balanced meals are available in an increasing number of fast food establishments (",
"    <a class=\"graphic graphic_table graphicRef73312 \" href=\"mobipreview.htm?27/2/27692\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/51,56\">",
"     51,56",
"    </a>",
"    ]. As children and adolescents tend to \"underestimate\" calorie content of their fast food choices, choosing fast food establishments that post calorie information prominently at the point of purchase encourages restraint and informed purchasing by customers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/48,57\">",
"     48,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MORE NUTRITIOUS FAST-FOOD CHOICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A steady diet of fast foods that is haphazard and that contains too much fat, too many calories; and too little fiber, vitamins, and minerals can be unhealthy for children and adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/58\">",
"     58",
"    </a>",
"    ]. However, an occasional fast food meal can fit into an otherwise well-balanced diet. It is important to look at the overall diet quality rather than focus on one food or one meal. Nutritional excesses or deficiencies should be compensated for at other meals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     General suggestions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents in focus groups report that the main barriers to making healthy nutritional choices are taste preferences for less healthy foods and a lack of concern about personal health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/59\">",
"     59",
"    </a>",
"    ]. Although eating out in fast food restaurants is a fact of life for many American families, clinicians, and parents can be powerful role models for their children and can teach them how to choose fast foods wisely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. The following represent general recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fill in \"nutrient gaps\" from a typical fast food meal by healthy snacks at home. Offer fresh fruits, vegetables, cheese and crackers, low-fat milk, calcium-fortified juices, and frozen yogurt as snacks. Making healthful food taste and look better and be more convenient also is important [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Encourage portion control; educate adolescents that anything that equates with bigness such as \"large,\" \"extra,\" \"double,\" or \"triple\" will be high in calories and fat. Recommend smaller portions, since a regular serving is enough for most children, or sharing with a parent or sibling.",
"     </li>",
"     <li>",
"      Look for whole grain foods, fruits, vegetables, and calcium-rich foods.",
"     </li>",
"     <li>",
"      Enjoy eating out, be adventurous, and visit a variety of types of ethnic fast food restaurants. Try Mexican, Asian, Italian, and seafood restaurants as well as those serving American fare. As with eating at home, variety is the key to a well-balanced diet [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When planning a fast food meal, try to choose an establishment that promotes healthier options at the point of purchase. This practice encourages some restraint and may help children learn how to make healthier purchases. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Portion size'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aim to remove the focus on individual foods as \"good\" or \"bad.\" Instead, provide information on how to evaluate the nutrient density of a food item. It is the total dietary intake that contributes to a healthy eating plan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/62,63\">",
"       62,63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4148213\">",
"    <span class=\"h2\">",
"     Specific suggestions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following specific suggestions can be used to improve the nutritional quality of meals at fast food establishments:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sandwiches &mdash; Request single-patty hamburgers, grilled and char-broiled chicken (rather than breaded and deep-fried), while limiting cheese, bacon, and mayonnaise. Mayonnaise can add about 80 calories (9 g of fat). Deli sandwiches made of lean turkey or roast beef (mustard only) provide less than 30 percent of their energy from fat. Low-fat extras such as lettuce, tomato, onions, mustard, and low-fat salad dressings make healthy sandwich toppings.",
"     </li>",
"     <li>",
"      Alternative main dishes &mdash; Try chili or soft tacos. Soft tacos have less fat than hard tacos because the tortilla has not been fried. Use salsa to add extra flavor; limit the use of high-fat sour cream and guacamole.",
"     </li>",
"     <li>",
"      Side dishes &mdash; Choose a baked potato rather than french fries, limiting the use of butter, sour cream, bacon bits, and shredded cheese. Vegetables or chili should be used as toppings. If available, separate side dishes of steamed vegetables supply vitamins A and C.",
"     </li>",
"     <li>",
"      Pizza &mdash; Order thin-crust pizzas made with low-fat cheese and vegetables or lower-fat meat, such as ham. Higher-fat sausage or pepperoni should be avoided.",
"     </li>",
"     <li>",
"      Salad &mdash; Avoid large amounts of high-fat items, such as regular fat-containing dressing, bacon bits, and shredded cheese. Assorted fresh fruits and vegetables, or beans add extra fiber, vitamins, and minerals.",
"     </li>",
"     <li>",
"      Beverages &mdash; Choose low-fat milk, yogurt shakes, or juice as substitutes for soft drinks.",
"     </li>",
"     <li>",
"      Desserts &mdash; Select low-fat frozen yogurt cones or sundaes and fresh fruit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/61/42967/abstract/64\">",
"       64",
"      </a>",
"      ]. Avoid fried pies and cookies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INFORMATION RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is possible to teach children and adolescents how to evaluate healthy food choices by allowing them to \"order\" from the menus of their favorite fast food restaurants on the internet. It is important to compare the fast food choices not only with other fast food options, but also with dietary recommendations for children, especially for energy intake (",
"    <a class=\"graphic graphic_table graphicRef80428 graphicRef68420 \" href=\"mobipreview.htm?10/3/10302\">",
"     table 3A-B",
"    </a>",
"    ). Guidelines for healthy eating are summarized on the United States Department of Agriculture (USDA) website",
"    <a class=\"external\" href=\"file://www.choosemyplate.gov/food-groups/\">",
"     ChooseMyPlate",
"    </a>",
"    , and in a separate UpToDate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28631?source=see_link&amp;anchor=H9#H9\">",
"     \"Dietary history and recommended dietary intake in children\", section on 'Recommended dietary intakes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Website",
"    <a class=\"external\" href=\"file://www.healthydiningfinder.com/\">",
"     www.HealthyDiningFinder.com",
"    </a>",
"    is a resource of healthier menu selections from 50,000 nationwide restaurants. These selections emphasize lean protein, fruits, vegetables, and whole grains. Featured menu items must meet specific nutrient criteria for calories, fat, and saturated fat. To be included, entrees must have the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lean meats, fruits",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vegetables, and 100 percent whole wheat.",
"     </li>",
"     <li>",
"      No more than 750 calories, 25 grams fat, 8 grams saturated fat. Side dishes, appetizers, and desserts must contain no more than 250 calories, 8 grams fat, and 3 grams saturated fat. Foods lower in sodium and cholesterol also are featured.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another website,",
"    <a class=\"external\" href=\"file://www.fastfoodfacts.info/\">",
"     www.fastfoodfacts.info",
"    </a>",
"    , provides a list of typical food selections from many of the common fast food restaurants. Each food selection contains tables that show the relative amounts of dietary energy, fat, and proportion of calories from fat in the particular item selected, or a comparison of several food items. In addition, many fast food restaurants provide nutrition information pamphlets upon request. In this way, fast foods are not necessarily seen as forbidden foods, but rather that some of the menu items are better choices to make.",
"   </p>",
"   <p>",
"    A number of other Websites also provide nutritional information about fast foods. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wake Forest University Baptist Medical Center Drive thru Diet",
"      <span class=\"nowrap\">",
"       (file://www.wakehealth.edu/Nutrition/Count+Your+Calories/dtd.htm).",
"      </span>",
"      The child or adolescent can access nutrition information of some of the largest fast food chains in America. &nbsp;",
"     </li>",
"     <li>",
"      Interactive fast food menu &ndash;",
"      <a class=\"external\" href=\"file://www.extension.org/pages/24398/interactive-fast-food-menu\">",
"       Cooperative extension system",
"      </a>",
"      <span class=\"nowrap\">",
"       (file://www.extension.org/pages/24398/interactive-fast",
"      </span>",
"      food-menu)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28991363\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequent consumption of fast food has adverse effects on nutrition because of excessive content of energy and fat, and low nutritional value (",
"      <a class=\"graphic graphic_table graphicRef62971 \" href=\"mobipreview.htm?25/9/25757\">",
"       table 1",
"      </a>",
"      ). Moreover, consumption of fast food is associated with other poor nutritional habits. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because fast food is widespread in the United States and many other countries, eliminating fast food consumption entirely is not a realistic goal for many families. Instead, the clinician should focus on reduction in fast food intake by providing nutritional education and suggesting healthier alternatives to the individual patient. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'More nutritious fast-food choices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common nutritional hazards of many fast foods are that they provide excessive energy (calories), total and saturated fat, cholesterol, and sodium, and are low in vitamins A and C,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/31/22005?source=see_link\">",
"       folic acid",
"      </a>",
"      , fiber, and calcium. In addition, portion sizes for many fast foods are in excess of typical caloric needs for most individuals, and marketing techniques further promote excessive consumption, by equating \"volume\" with \"value\". (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nutrient content'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Portion size'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many fast food establishments now offer some items with improved nutritional value, in addition to traditional selections. By selecting foods that are lower in fat content and higher in vitamins, minerals, and fiber, well-balanced meals are available in an increasing number of fast food establishments. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Opportunities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinician should provide general guidance to help their patients reduce the frequency and improve the nutritional value of their fast food consumption. In addition, detailed nutritional information about fast food is available through the internet, and the clinician can use these sites to review and discuss the patient&rsquo;s usual fast food choices. It is important to compare the fast food choices not only with other fast food options, but also with dietary recommendations for children, especially for energy intake (",
"      <a class=\"graphic graphic_table graphicRef80428 graphicRef68420 \" href=\"mobipreview.htm?10/3/10302\">",
"       table 3A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Information resources'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92759017\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Craig Jensen, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/1\">",
"      Briefel RR, Johnson CL. Secular trends in dietary intake in the United States. Annu Rev Nutr 2004; 24:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/2\">",
"      Fitzgerald CM, Kannan S, Sheldon S, Eagle KA. Effect of a promotional campaign on heart-healthy menu choices in community restaurants. J Am Diet Assoc 2004; 104:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/3\">",
"      Dumanovsky T, Nonas CA, Huang CY, et al. What people buy from fast-food restaurants: caloric content and menu item selection, New York City 2007. Obesity (Silver Spring) 2009; 17:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/4\">",
"      Guthrie JF, Lin BH, Frazao E. Role of food prepared away from home in the American diet, 1977-78 versus 1994-96: changes and consequences. J Nutr Educ Behav 2002; 34:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/5\">",
"      Bowers, DE. Cooking trends echo changing roles of women. Food Rev 2000; 23:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/6\">",
"      St-Onge MP, Keller KL, Heymsfield SB. Changes in childhood food consumption patterns: a cause for concern in light of increasing body weights. Am J Clin Nutr 2003; 78:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/7\">",
"      Jabs J, Devine CM. Time scarcity and food choices: an overview. Appetite 2006; 47:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/8\">",
"      Story M, Neumark-Sztainer D, French S. Individual and environmental influences on adolescent eating behaviors. J Am Diet Assoc 2002; 102:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/9\">",
"      Rydell SA, Harnack LJ, Oakes JM, et al. Why eat at fast-food restaurants: reported reasons among frequent consumers. J Am Diet Assoc 2008; 108:2066.",
"     </a>",
"    </li>",
"    <li>",
"     National Restaurant Association. Rapid response. Available at: www.restaurant.org/pressroom/rapid_response.cfm?ID=607 (Accessed on February 3, 3008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/11\">",
"      Bowman SA, Gortmaker SL, Ebbeling CB, et al. Effects of fast-food consumption on energy intake and diet quality among children in a national household survey. Pediatrics 2004; 113:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/12\">",
"      Paeratakul S, Ferdinand DP, Champagne CM, et al. Fast-food consumption among US adults and children: dietary and nutrient intake profile. J Am Diet Assoc 2003; 103:1332.",
"     </a>",
"    </li>",
"    <li>",
"     Yale University Rudd Center for Food Policy and Obesity. Fast food facts. file://www.fastfoodmarketing.org/fast_food_facts_in_brief.aspx (Accessed on May 23, 2011).",
"    </li>",
"    <li>",
"     Lin, BH, Guthrie, J, Blaylock, JR. The diets of America's children: influences of dining out, household characteristics, and nutrition knowledge. Washington, DC. US Department of Agriculture, Economic Research Service; 1999. Economic Report Number 746 (AER-746).",
"    </li>",
"    <li>",
"     National Restaurant Association. Restaurant industry to continue to be major driver in nation's economy through sales employment growth in 2008. Available at: www.restaurant.org/pressroom/pressrelease.cfm?ID=1535 (Accessed on February 3, 2008).",
"    </li>",
"    <li>",
"     National Restaurant Association. Restaurant industry forecast 2011. www.restaurant.org (Accessed on May 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/17\">",
"      Andreyeva T, Kelly IR, Harris JL. Exposure to food advertising on television: associations with children's fast food and soft drink consumption and obesity. Econ Hum Biol 2011; 9:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/18\">",
"      Harrison K, Marske AL. Nutritional content of foods advertised during the television programs children watch most. Am J Public Health 2005; 95:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/19\">",
"      Powell LM, Szczypka G, Chaloupka FJ. Adolescent exposure to food advertising on television. Am J Prev Med 2007; 33:S251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/20\">",
"      Thompson DA, Flores G, Ebel BE, Christakis DA. Comida en venta: after-school advertising on Spanish-language television in the United States. J Pediatr 2008; 152:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/21\">",
"      Powell LM, Szczypka G, Chaloupka FJ, Braunschweig CL. Nutritional content of television food advertisements seen by children and adolescents in the United States. Pediatrics 2007; 120:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/22\">",
"      Hall, S. Marketing to children: Growing the customers of tomorrow. Restaurants USA 1999; 19:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/23\">",
"      Sebastian RS, Wilkinson Enns C, Goldman JD. US adolescents and MyPyramid: associations between fast-food consumption and lower likelihood of meeting recommendations. J Am Diet Assoc 2009; 109:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/24\">",
"      O'Donnell SI, Hoerr SL, Mendoza JA, Tsuei Goh E. Nutrient quality of fast food kids meals. Am J Clin Nutr 2008; 88:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/25\">",
"      Boutelle KN, Fulkerson JA, Neumark-Sztainer D, et al. Fast food for family meals: relationships with parent and adolescent food intake, home food availability and weight status. Public Health Nutr 2007; 10:16.",
"     </a>",
"    </li>",
"    <li>",
"     Department of Health and Human Services. Healthy people 2010: National health promotion and disease prevention objectives. Washington, DC: U.S. Government Printing Office, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/27\">",
"      Thompson DR, Obarzanek E, Franko DL, et al. Childhood overweight and cardiovascular disease risk factors: the National Heart, Lung, and Blood Institute Growth and Health Study. J Pediatr 2007; 150:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/28\">",
"      Whincup PH, Gilg JA, Donald AE, et al. Arterial distensibility in adolescents: the influence of adiposity, the metabolic syndrome, and classic risk factors. Circulation 2005; 112:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/29\">",
"      Greer FR, Krebs NF, American Academy of Pediatrics Committee on Nutrition. Optimizing bone health and calcium intakes of infants, children, and adolescents. Pediatrics 2006; 117:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/30\">",
"      Van Horn L, McCoin M, Kris-Etherton PM, et al. The evidence for dietary prevention and treatment of cardiovascular disease. J Am Diet Assoc 2008; 108:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/31\">",
"      Holt EM, Steffen LM, Moran A, et al. Fruit and vegetable consumption and its relation to markers of inflammation and oxidative stress in adolescents. J Am Diet Assoc 2009; 109:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/32\">",
"      Dauchet L, Amouyel P, Hercberg S, Dallongeville J. Fruit and vegetable consumption and risk of coronary heart disease: a meta-analysis of cohort studies. J Nutr 2006; 136:2588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/33\">",
"      Uauy R, Solomons N. Diet, nutrition, and the life-course approach to cancer prevention. J Nutr 2005; 135:2934S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/34\">",
"      Nicklas T, Johnson R, American Dietetic Association. Position of the American Dietetic Association: Dietary guidance for healthy children ages 2 to 11 years. J Am Diet Assoc 2004; 104:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/35\">",
"      Robinson TN, Borzekowski DL, Matheson DM, Kraemer HC. Effects of fast food branding on young children's taste preferences. Arch Pediatr Adolesc Med 2007; 161:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/36\">",
"      Cottone E, Byrd-Bredbenner C. Knowledge and psychosocial effects of the film super size me on young adults. J Am Diet Assoc 2007; 107:1197.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Nutrition, American Academy of Pediatrics. Fast foods, organic foods, fad diets. In: Pediatric Nutrition Handbook, Kleinman, RE (Ed), 6th ed, American Academy of Pediatrics, Elk Grove Village, IL 2009. p. 275.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/38\">",
"      Nielsen SJ, Siega-Riz AM, Popkin BM. Trends in food locations and sources among adolescents and young adults. Prev Med 2002; 35:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/39\">",
"      Schmidt M, Affenito SG, Striegel-Moore R, et al. Fast-food intake and diet quality in black and white girls: the National Heart, Lung, and Blood Institute Growth and Health Study. Arch Pediatr Adolesc Med 2005; 159:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/40\">",
"      Colapinto CK, Fitzgerald A, Taper LJ, Veugelers PJ. Children's preference for large portions: prevalence, determinants, and consequences. J Am Diet Assoc 2007; 107:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/41\">",
"      Krebs NF, Himes JH, Jacobson D, et al. Assessment of child and adolescent overweight and obesity. Pediatrics 2007; 120 Suppl 4:S193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/42\">",
"      Ebbeling CB, Garcia-Lago E, Leidig MM, et al. Altering portion sizes and eating rate to attenuate gorging during a fast food meal: effects on energy intake. Pediatrics 2007; 119:869.",
"     </a>",
"    </li>",
"    <li>",
"     Duyff, RL. The American Dietetic Association Complete Food and Nutrition Guide. Chonimed Publishing, Minneapolis 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/44\">",
"      Johnson CM, Angell SY, Lederer A, et al. Sodium content of lunchtime fast food purchases at major US chains. Arch Intern Med 2010; 170:732.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Nutrition Board, National Academy of Science-National Research Council. Recommended dietary allowances, 10th ed, National Academy Press, Washington, DC 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/46\">",
"      American Academy of Pediatrics Committee on Nutrition: Statement on cholesterol. Pediatrics 1992; 90:469.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration, Questions and answers on the new menu and vending machines nutrition labeling requirements. Available at: file://www.fda.gov/Food/LabelingNutrition/ucm248731.htm#5 (Accessed on June 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/48\">",
"      Bassett MT, Dumanovsky T, Huang C, et al. Purchasing behavior and calorie information at fast-food chains in New York City, 2007. Am J Public Health 2008; 98:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/49\">",
"      Yamamoto JA, Yamamoto JB, Yamamoto BE, Yamamoto LG. Adolescent fast food and restaurant ordering behavior with and without calorie and fat content menu information. J Adolesc Health 2005; 37:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/50\">",
"      Tandon PS, Wright J, Zhou C, et al. Nutrition menu labeling may lead to lower-calorie restaurant meal choices for children. Pediatrics 2010; 125:244.",
"     </a>",
"    </li>",
"    <li>",
"     Tamborlane, WV (Ed). The Yale Guide to Children's Nutrition. Yale University Press, New Haven 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/52\">",
"      Yamamoto JA, Yamamoto JB, Yamamoto BE, Yamamoto LG. Adolescent calorie/fat menu ordering at fast food restaurants compared to other restaurants. Hawaii Med J 2006; 65:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/53\">",
"      Ebbeling CB, Sinclair KB, Pereira MA, et al. Compensation for energy intake from fast food among overweight and lean adolescents. JAMA 2004; 291:2828.",
"     </a>",
"    </li>",
"    <li>",
"     National Restaurant Association. Industry forecast predicts trends in healthier options and \"greener\" restaurants in 2009. Available at: www.restaurant.org/pressroom/pressrelease.cfm?ID=1726 (Accessed on April 7th, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/55\">",
"      Creel JS, Sharkey JR, McIntosh A, et al. Availability of healthier options in traditional and nontraditional rural fast-food outlets. BMC Public Health 2008; 8:395.",
"     </a>",
"    </li>",
"    <li>",
"     National Restaurant Association. Healthy kids meals, local produce, mini desserts among hottest menu trends for 2009, according to National Restaurant Association Research. Available at: www.restaurant.org/pressroom/pressrelease.cfm?ID=1708 (Accessed on April 7th, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/57\">",
"      Elbel B, Gyamfi J, Kersh R. Child and adolescent fast-food choice and the influence of calorie labeling: a natural experiment. Int J Obes (Lond) 2011; 35:493.",
"     </a>",
"    </li>",
"    <li>",
"     Illinois Nutrition Education and Training Program. Navigating in a Fast Food World. Available at: www.kidseatwell.org/parents/newsletter/NAVIGATINGINAFASTFOODWORLD.html (Accessed on February 3, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/59\">",
"      Neumark-Sztainer D, Story M, Perry C, Casey MA. Factors influencing food choices of adolescents: findings from focus-group discussions with adolescents. J Am Diet Assoc 1999; 99:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/60\">",
"      McBean LD, Miller GD. Enhancing the nutrition of America's youth. J Am Coll Nutr 1999; 18:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/61\">",
"      Sutherland LA, Beavers DP, Kupper LL, et al. Like parent, like child: child food and beverage choices during role playing. Arch Pediatr Adolesc Med 2008; 162:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/62\">",
"      O'Dea JA. Children and adolescents identify food concerns, forbidden foods, and food-related beliefs. J Am Diet Assoc 1999; 99:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42967/abstract/63\">",
"      Freeland-Graves J, Nitzke S. Position of the American Dietetic Association: total diet approach to communicating food and nutrition information. J Am Diet Assoc 2002; 102:100.",
"     </a>",
"    </li>",
"    <li>",
"     Wardlow, GM. Contemporary Nutrition: Issues and Insights, 3rd ed, Brown &amp; Benchmark Publishers, Dubuque 1997.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5352 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_61_42967=[""].join("\n");
var outline_f41_61_42967=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28991363\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NUTRITIONAL CONSIDERATIONS OF FAST FOODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Concerns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Nutrient content",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Portion size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4147846\">",
"      - Data on nutritional effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4147871\">",
"      - Association with obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Opportunities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MORE NUTRITIOUS FAST-FOOD CHOICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      General suggestions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4148213\">",
"      Specific suggestions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INFORMATION RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28991363\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92759017\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5352\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5352|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/9/25757\" title=\"table 1\">",
"      Typical fast food meals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/2/27692\" title=\"table 2\">",
"      Healthier fast food meals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/20/8525\" title=\"table 3A\">",
"      Energy requirements children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/26/36268\" title=\"table 3B\">",
"      Dietary composition children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/24/16778?source=related_link\">",
"      Adolescent eating habits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28631?source=related_link\">",
"      Dietary history and recommended dietary intake in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_61_42968="Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes";
var content_f41_61_42968=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/61/42968/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/61/42968/contributors\">",
"     Richard S Panush, MD, MACP, MACR",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/61/42968/contributors\">",
"     Neil Kramer, MD, FACR, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/61/42968/contributors\">",
"     Elliot D Rosenstein, MD, FACR, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/61/42968/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/61/42968/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/61/42968/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/61/42968/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/61/42968/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As much as 25 percent of rheumatic disease patients with systemic symptoms cannot be definitively diagnosed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Such patients were first described as having &ldquo;collagen&rdquo; or &ldquo;connective tissue&rdquo; diseases, since they shared similar clinical and pathologic features of widespread inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Subsequently, these patients have been considered to have diffuse or undifferentiated (or sometimes early undifferentiated) connective tissue diseases (UCTD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. Other patients with rheumatic diseases have systemic features that overlap two or more specific entities and also cannot be definitively diagnosed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/2,12-14\">",
"     2,12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasingly, the term &ldquo;systemic rheumatic disease&rdquo; has replaced collagen or connective tissue disease. This change reflects the recognition that these disorders probably represent perturbations of the immune system with resultant inflammatory tissue injury; the inciting events are not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Rheumatology (ACR) has used classification criteria to assist in the categorization and diagnosis of patients with rheumatic diseases. These classification criteria do not substitute for unique identification of etiologic, clinical, or immunopathologic features for systemic rheumatic diseases, which remain unknown for most of these disorders.",
"   </p>",
"   <p>",
"    Those disorders considered to be &ldquo;undifferentiated&rdquo; rheumatic diseases",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    overlap syndromes are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef78343 \" href=\"mobipreview.htm?14/5/14428\">",
"     table 1",
"    </a>",
"    ). Undifferentiated rheumatic diseases generally comprise one or more of the following clinical scenarios:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early Raynaud phenomenon alone (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Raynaud phenomenon'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Early inflammatory polyarthritis that does not fulfill ACR criteria for the diagnosis of rheumatoid arthritis (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Polyarthritis'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Nonspecific rash resembling the cutaneous findings found in defined rheumatic diseases, often associated with an interface dermatitis (ie, inflammation at the dermal-epidermal junction) (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Rash'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Patients who, despite manifesting multiple nonspecific clinical or serologic abnormalities, do not meet ACR criteria for the diagnosis of a specific rheumatic disease (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Early undifferentiated systemic rheumatic disease'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians must be cautious of diagnostic labeling that is not based upon an understanding of a unique etiology or pathogenesis of disease. Unless or until certain diagnoses can be established with confidence, these patients should be closely followed, while managing their major rheumatologic symptoms (eg, arthritis, glomerulonephritis) according to treatment standards [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RAYNAUD PHENOMENON",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Raynaud phenomenon (RP) may be an early sign of systemic rheumatic disease in as much as 10 percent of individuals. As an example, in one study of patients initially presenting with RP, 36 percent evolved into UCTD. Thumb involvement with RP may be more likely with secondary than primary RP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with RP should be evaluated with a careful history and physical exam, including nailfold capillaroscopy (which may be done in the office with a handheld lighted microscope or with an ophthalmoscope and immersion oil), testing for antinuclear antibodies (ANA), and, in selected cases, testing for the presence of cryoglobulins or other cryoprecipitable proteins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nailfold capillaroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of abnormal nailfold capillaroscopy (NC) in predicting the development of a defined CTD was emphasized by a study of 1024 patients with RP among whom 308 had neither serological findings nor clinical signs of CTD but did have NC pathological features suspicious for CTD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/17\">",
"     17",
"    </a>",
"    ]. Follow-up data were available for 133 patients. After a mean follow-up of 6.5 years, 109 patients had developed a CTD (mostly diffuse and limited cutaneous systemic sclerosis, sometimes with findings consistent with the CREST syndrome [calcinosis, RP, esophageal dysmotility, sclerodactyly, and telangiectasia syndrome] or mixed connective tissue disease [MCTD]), and 24 patients did not show any clinical signs or serological markers for a CTD after a mean follow-up of 8.5 years. The presence of giant capillaries, avascular fields, and irregular architecture of nailfold capillaries was highly predictive for the development of a CTD in patients with RP.",
"   </p>",
"   <p>",
"    In addition to positive findings on NC, other features predictive of underlying systemic rheumatic disease include older age of onset, severe digital ischemia, asymmetric attacks, and the presence of ANA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/18\">",
"     18",
"    </a>",
"    ]. The presence of ANA alone should not lead to a premature diagnosis of underlying systemic rheumatic disease. In a prospective study of 1039 patients with RP, there were 129 who had a positive ANA among 819 subjects who had no systemic rheumatic disease at initial presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/19\">",
"     19",
"    </a>",
"    ]. A defined rheumatic disease developed in only 22 percent of this subset after a mean of three years of follow-up.",
"   </p>",
"   <p>",
"    In contrast to the lack of predictive value of ANA, the presence of anticentromere antibodies is suggestive of the eventual development of CREST syndrome. In one series of 85 patients with RP, the presence of anticentromere antibodies had a sensitivity of 60 percent and specificity of 98 percent for the development of CREST among those presenting with primary RP or with possible connective tissue disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     POLYARTHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to confidently diagnose rheumatoid arthritis (RA) early in its course in order to identify those patients who might benefit from early aggressive therapy. This follows from an appreciation that early, irreversible joint damage can occur within the first six months of onset of RA and that a narrow window of opportunity exists in which to optimally introduce effective antirheumatic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18521?source=see_link\">",
"     \"Assessing the probability of developing rheumatoid arthritis in patients with undifferentiated inflammatory arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who meet ACR criteria for classic RA when first evaluated, approximately 90 percent carry the same diagnosis five years later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/11,21\">",
"     11,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least as common as RA is a heterogeneous group of patients with the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms of inflammatory joint disease such as diffuse or migratory arthralgias, symmetrical or asymmetric polyarthritis or oligoarthritis, migratory polyarthritis, or a convincing history of joint swelling",
"     </li>",
"     <li>",
"      A history which frequently includes prolonged morning stiffness",
"     </li>",
"     <li>",
"      An elevated erythrocyte sedimentation rate and positive ANA or rheumatoid factor titers",
"     </li>",
"     <li>",
"      A dramatic response to antiinflammatory therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings are suggestive of RA but do not fulfill ACR criteria for this diagnosis. Approximately 10 percent of such patients will ultimately fulfill diagnostic criteria for another systemic rheumatic disease (lupus, systemic sclerosis, polymyositis, or a spondyloarthropathy), and 5 to 10 percent will acquire other features of undifferentiated systemic rheumatic disease but will still not be diagnosable as having a specific rheumatic disease.",
"   </p>",
"   <p>",
"    In two large prospective studies, approximately 20 percent of such patients evolved into definite RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/11,21\">",
"     11,21",
"    </a>",
"    ]. A consistent pattern of predictive variables could not be identified in the multivariate analyses other than higher small joint counts and higher erythrocyte sedimentation rate at year one in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/11\">",
"     11",
"    </a>",
"    ] and rheumatoid factor positivity in the other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis is generally considered different between those with undifferentiated arthritis (UA) and those with RA. The following are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report of 1141 such patients (638 with UA and 503 with RA), complete resolution of symptoms occurred in 54 percent of those with undifferentiated polyarthritis versus only 7.5 percent at seven years in those with RA at presentation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a Dutch study of the one-year outcome of patients with UA found that 42 percent of patients had progressive disease, most often identified among those with older age, higher disease activity, and arthritis of the hands at baseline. With the availability of potent medications to arrest the rheumatoid process, the authors concluded that treatment should be directed towards the severity of the presentation rather than the diagnostic categorization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar outcomes are seen for patients presenting with either RA or UA evolving into RA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early intervention with a disease-modifying antirheumatic drug (DMARD) may alter the natural progression from UA to RA. This was illustrated in a study that randomly assigned 110 patients with UA to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/26\">",
"     26",
"    </a>",
"    ]. Dose was adjusted based upon disease activity score and was then tapered and discontinued after 12 months. Progression from UA to RA occurred in a significantly smaller proportion of those receiving MTX than placebo (40 versus 53 percent, respectively). Fewer MTX treated patients showed radiographic progression over 18 months. Certain clinical features (sex, age, morning stiffness, localization of symptoms, tender and swollen joint counts, C-reactive protein, rheumatoid factor positivity, and presence of anticyclic citrullinated",
"    <span class=\"nowrap\">",
"     protein/peptide",
"    </span>",
"    [CCP] antibodies) could predict risk of developing RA and, therefore, could allow individualization of therapeutic decisions for patients with early, undifferentiated arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with early undifferentiated arthritis, serologic testing for anti-CCP has been demonstrated to be valuable in predicting progression to RA. This was illustrated in a prospective study of 346 patients with arthritis of less than two years&rsquo; duration who did not meet classification criteria for any specific type of arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/28\">",
"     28",
"    </a>",
"    ]. In this group of patients, 69 were anti-CCP antibody positive, and 64 of them (93 percent) met classification criteria for RA in the subsequent three years. In contrast, among the 249 patients who were initially anti-CCP negative, 63 (25 percent) developed sufficient criteria to establish the presence of RA during the same follow-up period. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33528?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Anti-citrullinated peptide antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unconventional serologic findings (eg, IgA rheumatoid factor, pyridinoline) have also been noted to help predict the later development of erosive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of ultrasound or magnetic resonance imaging (MRI), which offers the ability to identify synovitis, bone edema, and erosions prior to the development of classical x-ray changes, may help separate those patients with the development of RA from patients with less aggressive inflammatory joint disease. An algorithm including MRI-proven early joint damage in conjunction with autoantibodies has been promoted to predict progression from UA to RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/30\">",
"     30",
"    </a>",
"    ]. A study using MRI found more destructive change (synovial thickening, marrow edema, and erosions) in patients with RA and more enthesopathy in patients with spondyloarthropathy than in patients with undifferentiated arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/31\">",
"     31",
"    </a>",
"    ]. In patients with undifferentiated spondyloarthropathies, positive testing for HLA-B27 and the presence of buttock pain predicted evolution to a definable disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the revisions incorporated in the 2010 American College of",
"    <span class=\"nowrap\">",
"     Rheumatology/European",
"    </span>",
"    League Against Rheumatism RA classification criteria, including the presence of anti-CCP, it was anticipated that the diagnosis of RA would be entertained in individuals with much earlier presentations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. This has been borne out by studies documenting that the UA is less prevalent and milder in its presentation and outcome since the 2010 criteria were instituted, suggesting that patients with unfavorable characteristics are more frequently classified as having RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RASH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rashes with clinical and histopathological features suggestive of, but not diagnostic for, subacute cutaneous LE were identified in 47 cases (approximately 9 percent) in a study of 526 individuals who had an interface dermatitis and clinical symptoms of UCTD (out of a total of 892 individuals with UCTD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/36\">",
"     36",
"    </a>",
"    ]. The skin disease consisted of erythematous macules, patches, or papules with delicate scale, found most frequently on thighs, lower legs, upper arms, upper back, and shoulders, in that order. Skin biopsies in 15 of 47 of these individuals showed mild lymphocyte interface dermatitis, superficial perivascular infiltrates of mononuclear inflammatory cells that spared eccrine glands, patchy dermal mucin, and occasional lymphocytic vasculopathy. Immunofluorescent staining was not performed. Of interest to the authors of the study, this form of dermatitis was more common in patients with antithyroid antibodies (9 percent) than in those without such autoantibodies (2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NONSPECIFIC INTERSTITIAL PNEUMONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial lung disease (ILD, also known as idiopathic interstitial pneumonia [IIP]) may precede or occur at or after onset of various connective tissue and rheumatic disorders. A histologic pattern referred to as nonspecific interstitial pneumonia pattern (NSIP) is commonly found in lung biopsy specimens of patients with many rheumatic and connective tissue diseases, including systemic lupus erythematosus, Sj&ouml;gren's syndrome, systemic sclerosis, and dermatomyositis. Interestingly, the histologic pattern of usual interstitial pneumonia (UIP), associated with a poorer prognosis, is the more common presentation of ILD in association with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42393?source=see_link\">",
"     \"Nonspecific interstitial pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The NSIP pattern of lung injury has also been noted to be a common pattern in patients who are classified as having UCTD. This was illustrated in a case-control study of 28 patients with one or more clinical features of UCTD and ILD and of a control group of 47 patients with ILD in the absence of UCTD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/38\">",
"     38",
"    </a>",
"    ]. Subgroups of UCTD and control patients without clinical features of UCTD underwent lung biopsy (18 and 22 patients, respectively). The histologic pattern of NSIP was most common in those with UCTD (83 percent) with other patterns including usual interstitial pneumonia (UIP), organizing pneumonia, and nonclassifiable fibrosis less often noted (6 percent each). In contrast, in patients with idiopathic interstitial pneumonia (IIP) and no clinical features of UCTD, UIP was present in 86 percent, and NSIP was present in only 9 percent. In a series of 68 patients who had presented with IIP and who were followed prospectively for 11 years, 13 (19 percent) eventually developed classifiable CTD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is uncertain whether patients with UCTD and ILD are more or less likely to develop a classifiable connective tissue or systemic rheumatic disease. In the study cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/38\">",
"     38",
"    </a>",
"    ], patients with lung involvement had pulmonary symptoms such as cough or dyspnea for a mean of 3.5 years before the time that features of UCTD were assessed.",
"   </p>",
"   <p>",
"    The concept of &ldquo;lung-dominant CTD&rdquo; has been proposed to characterize those patients with NSIP who had certain histopathologic features (diffuse perivascular collagen, aggressive pleuritis, lymphoid aggregates with germinal center formation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prominent plasma cell infiltrates) or positive serologies (antisynthetase, Scl-70, SSA, or CCP antibodies) but who lacked sufficient extra-pulmonary clinical features to be classified as having a specific rheumatic disease. This may be an important distinction, since the prognosis and response to therapy for connective tissue disease (CTD)-associated NSIP are more favorable than for IIP that is not associated with CTD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/40\">",
"     40",
"    </a>",
"    ]. Even in patients with UIP, the search for signs of an underlying CTD may be warranted because of the significantly better survival of UIP associated with CTD than IIP that is not associated with CTD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/37\">",
"     37",
"    </a>",
"    ]. What remains lacking, however, are studies evaluating the optimal immunosuppressive regimens and duration of therapy for patients with CTD-associated ILD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EARLY UNDIFFERENTIATED SYSTEMIC RHEUMATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who do not present with a clearly defined autoimmune syndrome or who have overlapping features of two or more diseases have been estimated to comprise 15 to 25 percent of tertiary rheumatology referrals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. One of the difficulties of making a specific diagnosis of a discrete systemic rheumatic disease is that several clinical features may be shared by RA, Sj&ouml;gren's syndrome, systemic lupus erythematosus (SLE), systemic sclerosis, and inflammatory myopathy. These include RP, polyarthritis, interstitial lung disease (ILD), pleuritis, or, less often, pericarditis and small vessel vasculitis.",
"   </p>",
"   <p>",
"    Another part of the diagnostic problem is that these various diseases may share serological abnormalities. This is particularly true for ANA, rheumatoid factor,",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-La/SSB.",
"    </span>",
"    Some antibodies, however, have greater diagnostic value. These include anticentromere and antitopoisomerase-I (Scl-70) antibodies in limited cutaneous systemic sclerosis (CREST syndrome) and diffuse scleroderma; anti-CCP antibodies in RA; and anti-Sm, anti-dsDNA, and antiphospholipid antibodies in lupus (",
"    <a class=\"graphic graphic_table graphicRef58564 graphicRef71307 \" href=\"mobipreview.htm?38/63/39934\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=see_link\">",
"     \"Measurement and clinical significance of antinuclear antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients presenting with incompletely expressed rheumatic disease and nonspecific autoantibodies are designated as having undifferentiated systemic rheumatic (connective tissue) disease (UCTD). A premature diagnosis of one of the discrete rheumatic diseases does not serve patients well, since the undifferentiated nature of the syndrome usually persists. In general, among those destined to develop a defined connective tissue disease, evolution occurs early in the course of the presentation, within two to five years in the majority of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evolution to a discrete rheumatic disease is somewhat more common than resolution of the syndrome. Illustrative results of prospective studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a North American series of 143 patients followed prospectively for up to 10 years, a definite rheumatic disease was observed in 29 percent of individuals (SLE in 13 percent, systemic sclerosis in 15 percent, RA in 3 percent, and mixed connective tissue disease [MCTD] in 3 percent), while complete remission occurred in 6 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. In an Italian series of 165 patients followed for five years, a defined rheumatic disease developed in only 10 patients (SLE in five, Sj&ouml;gren&rsquo;s syndrome in three, polymyositis in one, and MCTD in one), while 19 became asymptomatic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 665 Hungarian patients followed for five years, evolution to a well-defined autoimmune syndrome occurred in 35 percent of patients, with 28 developing SLE, 26 MCTD, 19 systemic sclerosis, 45 Sj&ouml;gren&rsquo;s syndrome, 3",
"      <span class=\"nowrap\">",
"       poly-/dermatomyositis,",
"      </span>",
"      87 RA, and 22 &ldquo;systemic vasculitis,&rdquo; while 65 percent remained in the UCTD category. Among all patients in this study, complete remission occurred in only 12 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A multicenter study evaluated a cohort of 213 patients with symptoms of early undifferentiated systemic rheumatic disease for at least one year who were then followed for five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/11\">",
"       11",
"      </a>",
"      ]. The rate of progression to RA or SLE was 20 and 13 percent, respectively. The patients developing lupus were more likely to have been younger, to have been African-American, and to have had alopecia, serositis, discoid lesions, a positive Coombs test, a homogeneous ANA pattern, anti-dsDNA and anti-Sm antibodies,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a false positive test for syphilis; the presence of anti-Sm antibodies, discoid lesions, homogeneous ANA, and serositis were the strongest predictors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the Hungarian study noted above, the development of skin manifestations or cardiac complications was the greatest predictor of development of SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/46\">",
"     46",
"    </a>",
"    ]. In another study of 83 Italian patients with UCTD followed for more than five years, 22 percent developed SLE (one patient developed Sj&ouml;gren&rsquo;s syndrome). The presence of anticardiolipin antibodies and multiple antibody specificities was correlated with lupus development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/47\">",
"     47",
"    </a>",
"    ]. In a study of 148 UCTD patients with antibodies to",
"    <span class=\"nowrap\">",
"     Ro/SSA,",
"    </span>",
"    24 percent developed a defined condition, mainly SLE and Sj&ouml;gren&rsquo;s syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/48\">",
"     48",
"    </a>",
"    ]. The specificity of",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    may predict the evolution of the condition in that those with isolated antibodies to the 60 kD antigen were more likely to develop SLE, while those with antibodies to both 52 and 60 kD antigens correlated with development of Sj&ouml;gren&rsquo;s syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/49\">",
"     49",
"    </a>",
"    ]. Other data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/50\">",
"     50",
"    </a>",
"    ] suggest that older and female patients with recent-onset inflammatory polyarthritis tend to fare worse than others.",
"   </p>",
"   <p>",
"    As noted above, there are some patients who will develop manifestations of more than one discrete systemic rheumatic syndrome. Some of these conditions occur with sufficient frequency that they have been given their own unofficial designations: RA and SLE = &ldquo;rhupus,&rdquo; and systemic sclerosis and dermatomyositis = &ldquo;sclerodermatomyositis.&rdquo; Arguably, the most well-defined of these overlap syndromes is mixed connective tissue disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3447?source=see_link\">",
"     \"Definition and diagnosis of mixed connective tissue disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective analysis of the manifestations of patients with overlap syndromes noted that patients with rhupus tend to develop manifestations sequentially, whereas those with sclerodermatomyositis tend to have simultaneous presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients with rhupus, in addition to clinical and serologic findings consistent with SLE, may have radiographic evidence of erosive arthropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/14\">",
"     14",
"    </a>",
"    ]. The finding of elevated values of anti-CCP antibodies in some patients with rhupus supports the concept that, in some patients, this overlap syndrome may represent a true concordance of the two diseases rather than an atypical presentation of the arthropathy of SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Almost without exception, treatment is directed to the particular clinical manifestations and is not predicated on a definitive diagnosis. In one series, for example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    was most effective for the treatment of arthritis and dermatitis but had little effect on central nervous system abnormalities or on serositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/53\">",
"     53",
"    </a>",
"    ]. An intriguing report asserted the importance of vitamin D supplementation for patients with UCTD who are deficient, documenting improvement in immunoregulatory function",
"    <span class=\"nowrap\">",
"     (Treg/T17",
"    </span>",
"    ratio) and suggesting that continuous vitamin D treatment might inhibit the transition of UCTD to defined CTDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to patients either with undifferentiated rheumatic disease or with an overlap syndrome is summarized in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef55672 \" href=\"mobipreview.htm?2/16/2304\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients presenting without an obvious diagnosis need thoughtful evaluation and examination with attention to the diagnostic entities listed in the table (",
"    <a class=\"graphic graphic_table graphicRef78343 \" href=\"mobipreview.htm?14/5/14428\">",
"     table 1",
"    </a>",
"    ). Studies that should be obtained depend upon the presenting clinical features. These might include antinuclear antibodies; anti-dsDNA, -Sm, -RNP, -centromere,",
"    <span class=\"nowrap\">",
"     -Ro/SSA,",
"    </span>",
"    <span class=\"nowrap\">",
"     -La/SSB,",
"    </span>",
"    -Jo-1, -Scl-70, and -PM1 antibodies; rheumatoid factors; anti-CCP antibodies; erythrocyte sedimentation rate; and nailfold capillaroscopy (",
"    <a class=\"graphic graphic_table graphicRef58564 graphicRef71307 \" href=\"mobipreview.htm?38/63/39934\">",
"     table 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A specific diagnosis should be made only when patients fulfill appropriate classification criteria; these patients should be managed appropriately for that diagnosis. Other patients should be followed and reassessed periodically and should be managed according to their major rheumatologic symptom(s). As noted above, patients with undifferentiated arthritis have a high rate of spontaneous remission (54 percent in one report) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/61/42968/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1478559\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with undifferentiated rheumatic diseases",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      overlap syndromes who cannot be definitely diagnosed with a well-characterized systemic rheumatic disease may include up to 25 percent of rheumatic disease patients. These patients often exhibit one of several disease patterns, manifesting multiple nonspecific clinical or serologic abnormalities, sometimes of more than one defined rheumatic disorder (",
"      <a class=\"graphic graphic_table graphicRef78343 \" href=\"mobipreview.htm?14/5/14428\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Raynaud phenomenon (RP) may be an early sign of systemic rheumatic disease in as much as 10 percent of individuals, but one-third of such patients may evolve into an undefined connective tissue disease syndrome (UCTD). Patients with RP should be evaluated with a careful history and physical exam, including nailfold capillaroscopy, testing for antinuclear antibodies, and, in selected cases, testing for the presence of cryoglobulins or other cryoprecipitable proteins. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Raynaud phenomenon'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Nailfold capillaroscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A heterogeneous group of patients may exhibit symptoms and signs of inflammatory arthritis suggestive but not diagnostic of rheumatoid arthritis (RA), with an elevated erythrocyte sedimentation rate and a positive ANA or rheumatoid factor and with a dramatic response to antiinflammatory therapy. About 10 percent of such patients ultimately fulfill criteria for another systemic rheumatic disease, and 5 to 10 percent will acquire other features of systemic rheumatic disease but still cannot be diagnosed with a specific well-differentiated rheumatic disorder. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Polyarthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interstitial lung disease (ILD) may precede or occur at or after onset of various connective tissue and rheumatic disorders. A histologic pattern referred to as nonspecific interstitial pneumonia pattern (NSIP) is commonly found in lung biopsy specimens of patients with ILD associated with UCTD, SLE, Sj&ouml;gren's syndrome, systemic sclerosis, and dermatomyositis. The search for an underlying CTD in patients with ILD is warranted due to the generally more favorable prognosis compared with idiopathic disease. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nonspecific interstitial pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who present with undifferentiated systemic rheumatic (connective tissue) disease or who have overlapping clinical or serologic features of two or more diseases have been estimated to comprise 15 to 25 percent of tertiary rheumatology referrals. A premature diagnosis of one of the discrete rheumatic diseases should be avoided, since the undifferentiated nature of the syndrome usually persists. Among those destined to develop a defined connective tissue disease, which is more common than resolution of the syndrome, evolution generally occurs within two to five years. Treatment is generally directed to the particular clinical manifestations. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Early undifferentiated systemic rheumatic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients either with undifferentiated rheumatic disease or with an overlap syndrome should undergo a careful diagnostic evaluation (",
"      <a class=\"graphic graphic_algorithm graphicRef55672 \" href=\"mobipreview.htm?2/16/2304\">",
"       algorithm 1",
"      </a>",
"      ), which considers the most likely diagnostic entities (",
"      <a class=\"graphic graphic_table graphicRef78343 \" href=\"mobipreview.htm?14/5/14428\">",
"       table 1",
"      </a>",
"      ). Studies that should be obtained depend upon the presenting clinical features (",
"      <a class=\"graphic graphic_table graphicRef58564 graphicRef71307 \" href=\"mobipreview.htm?38/63/39934\">",
"       table 2A-B",
"      </a>",
"      ). A specific diagnosis should be made only when patients fulfill appropriate classification criteria; other patients should be followed and reassessed periodically and should be managed according to their major rheumatologic symptom(s). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Approach to the patient'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dubois EL, Wallace DJ. Differential diagnosis. In: Dubois' Lupus Erythematosus, Wallace DJ, Dubois EL (Eds), Lea and Febiger, Philadelphia 1987. p.470.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/2\">",
"      Cervera R, Khamashta MA, Hughes GR. 'Overlap' syndromes. Ann Rheum Dis 1990; 49:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/3\">",
"      KLEMPERER P. The concept of collagen diseases in medicine. Am Rev Respir Dis 1961; 83:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/4\">",
"      KLEMPERER P. The concept of connective-tissue disease. Circulation 1962; 25:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/5\">",
"      Doria A, Mosca M, Gambari PF, Bombardieri S. Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both? J Rheumatol 2005; 32:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/6\">",
"      LeRoy EC, Maricq HR, Kahaleh MB. Undifferentiated connective tissue syndromes. Arthritis Rheum 1980; 23:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/7\">",
"      Kallenberg CG. Overlapping syndromes, undifferentiated connective tissue disease, and other fibrosing conditions. Curr Opin Rheumatol 1993; 5:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/8\">",
"      Alarc&oacute;n GS, Williams GV, Singer JZ, et al. Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease. J Rheumatol 1991; 18:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/9\">",
"      Clegg DO, Williams HJ, Singer JZ, et al. Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. J Rheumatol 1991; 18:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/10\">",
"      Bulpitt KJ, Clements PJ, Lachenbruch PA, et al. Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993; 118:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/11\">",
"      Alarc&oacute;n GS, Willkens RF, Ward JR, et al. Early undifferentiated connective tissue disease. IV.Musculoskeletal manifestations in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of patients with well-established connective tissue diseases: followup analyses in patients with unexplained polyarthritis and patients with rheumatoid arthritis at baseline. Arthritis Rheum 1996; 39:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/12\">",
"      Panush RS, Greer JM, Morshedian KK. What is lupus? What is not lupus? Rheum Dis Clin North Am 1993; 19:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/13\">",
"      Greer JM, Panush RS. Incomplete lupus erythematosus. Arch Intern Med 1989; 149:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/14\">",
"      Panush RS, Edwards NL, Longley S, Webster E. 'Rhupus' syndrome. Arch Intern Med 1988; 148:1633.",
"     </a>",
"    </li>",
"    <li>",
"     Hellman D, Johnson J, Liang M, et al. Rheumatology syllabus, Medical Knowledge Self Assessment Program 11, Sergent J (Ed), American College of Physicians, Philadelphia, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/16\">",
"      Chikura B, Moore T, Manning J, et al. Thumb involvement in Raynaud's phenomenon as an indicator of underlying connective tissue disease. J Rheumatol 2010; 37:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/17\">",
"      Meli M, Gitzelmann G, Koppensteiner R, Amann-Vesti BR. Predictive value of nailfold capillaroscopy in patients with Raynaud's phenomenon. Clin Rheumatol 2006; 25:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/18\">",
"      Kallenberg CG. Early detection of connective tissue disease in patients with Raynaud's phenomenon. Rheum Dis Clin North Am 1990; 16:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/19\">",
"      Landry GJ, Edwards JM, McLafferty RB, et al. Long-term outcome of Raynaud's syndrome in a prospectively analyzed patient cohort. J Vasc Surg 1996; 23:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/20\">",
"      Kallenberg CG, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988; 47:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/21\">",
"      Wolfe F, Ross K, Hawley DJ, et al. The prognosis of rheumatoid arthritis and undifferentiated polyarthritis syndrome in the clinic: a study of 1141 patients. J Rheumatol 1993; 20:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/22\">",
"      Hitchon CA, Peschken CA, Shaikh S, El-Gabalawy HS. Early undifferentiated arthritis. Rheum Dis Clin North Am 2005; 31:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/23\">",
"      Marzo-Ortega H, Cawkwell L, Green MJ. Early oligoarthritis. Rheum Dis Clin North Am 2005; 31:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/24\">",
"      Jansen LM, van Schaardenburg D, van der Horst-Bruinsma IE, Dijkmans BA. One year outcome of undifferentiated polyarthritis. Ann Rheum Dis 2002; 61:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/25\">",
"      van Aken J, van Dongen H, le Cessie S, et al. Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study. Ann Rheum Dis 2006; 65:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/26\">",
"      van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007; 56:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/27\">",
"      van der Helm-van Mil AH, le Cessie S, van Dongen H, et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007; 56:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/28\">",
"      van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004; 50:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/29\">",
"      Le Lo&euml;t X, Brazier M, Mejjad O, et al. Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: a simple model of prediction from a conservatively treated community-based inception cohort. Arthritis Care Res (Hoboken) 2010; 62:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/30\">",
"      Tamai M, Kawakami A, Uetani M, et al. A prediction rule for disease outcome in patients with undifferentiated arthritis using magnetic resonance imaging of the wrists and finger joints and serologic autoantibodies. Arthritis Rheum 2009; 61:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/31\">",
"      Emad Y, Ragab Y, Shaarawy A, et al. Can magnetic resonance imaging differentiate undifferentiated arthritis based on knee imaging? J Rheumatol 2009; 36:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/32\">",
"      Sampaio-Barros PD, Bortoluzzo AB, Conde RA, et al. Undifferentiated spondyloarthritis: a longterm followup. J Rheumatol 2010; 37:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/33\">",
"      Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/34\">",
"      Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/35\">",
"      Krabben A, Huizinga TW, van der Helm-van Mil AH. Undifferentiated arthritis characteristics and outcomes when applying the 2010 and 1987 criteria for rheumatoid arthritis. Ann Rheum Dis 2012; 71:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/36\">",
"      Cheng W, Gilliam AC, Castrovinci A, Pazirandeh M. Anti-thyroid autoantibody-associated interface dermatitis in individuals with undifferentiated connective tissue disease--an unrecognized subset of autoimmune disease? J Rheumatol 2007; 34:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/37\">",
"      de Lauretis A, Veeraraghavan S, Renzoni E. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis 2011; 8:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/38\">",
"      Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 2007; 176:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/39\">",
"      Homma Y, Ohtsuka Y, Tanimura K, et al. Can interstitial pneumonia as the sole presentation of collagen vascular diseases be differentiated from idiopathic interstitial pneumonia? Respiration 1995; 62:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/40\">",
"      Fischer A, West SG, Swigris JJ, et al. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest 2010; 138:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/41\">",
"      Satoh M, Chan EK, Sobel ES, et al. Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Expert Rev Clin Immunol 2007; 3:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/42\">",
"      Mosca M, Tani C, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a new frontier for rheumatology. Best Pract Res Clin Rheumatol 2007; 21:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/43\">",
"      Williams HJ, Alarc&oacute;n GS, Neuner R, et al. Early undifferentiated connective tissue disease. V. An inception cohort 5 years later: disease remissions and changes in diagnoses in well established and undifferentiated connective tissue diseases. J Rheumatol 1998; 25:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/44\">",
"      Williams HJ, Alarcon GS, Joks R, et al. Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol 1999; 26:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/45\">",
"      Danieli MG, Fraticelli P, Franceschini F, et al. Five-year follow-up of 165 Italian patients with undifferentiated connective tissue diseases. Clin Exp Rheumatol 1999; 17:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/46\">",
"      Bodolay E, Csiki Z, Szekanecz Z, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol 2003; 21:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/47\">",
"      Mosca M, Neri R, Bencivelli W, et al. Undifferentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years. J Rheumatol 2002; 29:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/48\">",
"      Cavazzana I, Franceschini F, Belfiore N, et al. Undifferentiated connective tissue disease with antibodies to Ro/SSa: clinical features and follow-up of 148 patients. Clin Exp Rheumatol 2001; 19:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/49\">",
"      Belfiore N, Rossi S, Bobbio-Pallavicini F, et al. Anti-Ro(SS-A) 52 kDa and 60 kDa specificities in undifferentiated connective tissue disease. Joint Bone Spine 2000; 67:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/50\">",
"      Camacho EM, Verstappen SM, Lunt M, et al. Influence of age and sex on functional outcome over time in a cohort of patients with recent-onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken) 2011; 63:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/51\">",
"      Rodr&iacute;guez-Reyna TS, Alarc&oacute;n-Segovia D. Overlap syndromes in the context of shared autoimmunity. Autoimmunity 2005; 38:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/52\">",
"      Amezcua-Guerra LM, Springall R, Marquez-Velasco R, et al. Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study. Arthritis Res Ther 2006; 8:R144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/53\">",
"      Wise CM, Vuyyuru S, Roberts WN. Methotrexate in nonrenal lupus and undifferentiated connective tissue disease--a review of 36 patients. J Rheumatol 1996; 23:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/61/42968/abstract/54\">",
"      Zold E, Szodoray P, Nakken B, et al. Alfacalcidol treatment restores derailed immune-regulation in patients with undifferentiated connective tissue disease. Autoimmun Rev 2011; 10:155.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1831 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-EA571C30FB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_61_42968=[""].join("\n");
var outline_f41_61_42968=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1478559\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RAYNAUD PHENOMENON",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nailfold capillaroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      POLYARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RASH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NONSPECIFIC INTERSTITIAL PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EARLY UNDIFFERENTIATED SYSTEMIC RHEUMATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1478559\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1831\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1831|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?2/16/2304\" title=\"algorithm 1\">",
"      Algorithm for overlap disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1831|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/5/14428\" title=\"table 1\">",
"      Undifferentiated overlap synd",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/31/30205\" title=\"table 2A\">",
"      ANA disease associations I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/7/28797\" title=\"table 2B\">",
"      ANA disease associations II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18521?source=related_link\">",
"      Assessing the probability of developing rheumatoid arthritis in patients with undifferentiated inflammatory arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33528?source=related_link\">",
"      Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3447?source=related_link\">",
"      Definition and diagnosis of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42393?source=related_link\">",
"      Nonspecific interstitial pneumonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_61_42969="Nicardipine: Drug information";
var content_f41_61_42969=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nicardipine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/10/12453?source=see_link\">",
"    see \"Nicardipine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/38/32361?source=see_link\">",
"    see \"Nicardipine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cardene&reg; I.V.;",
"     </li>",
"     <li>",
"      Cardene&reg; SR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F201215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, Dihydropyridine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F201182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Angina:",
"     </b>",
"     Immediate release: Oral: 20 mg 3 times/day; usual range: 60-120 mg/day; increase dose at 3-day intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     Initial: 20 mg 3 times/day; usual: 20-40 mg 3 times/day (allow 3 days between dose increases)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Sustained release:",
"     </i>",
"     Initial: 30 mg twice daily, titrate up to 60 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The total daily dose of immediate-release product may not automatically be equivalent to the daily sustained-release dose; use caution in converting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute hypertension:",
"     </b>",
"     I.V.: Initial: Initial: 5 mg/hour increased by 2.5 mg/hour every 5 minutes (for rapid titration) to every 15 minutes (for gradual titration) up to a maximum of 15 mg/hour; rapidly titrated patients, consider reduction to 3 mg/hour after response is achieved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Arterial hypertension in acute ischemic stroke (unlabeled use [Adams, 2007; Jauch, 2010]):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patient otherwise eligible for reperfusion treatment (eg, alteplase):",
"     </i>",
"     Blood pressure (BP): Systolic &gt;185 mm Hg or diastolic &gt;110 mm Hg: 5 mg/hour; titrate by 2.5 mg/hour at 5-15 minute intervals (maximum dose: 15 mg/hour). When goal BP obtained, reduce dose to 3 mg/hour. If BP does not decline and remains &gt;185/110 mm Hg, alteplase should not be administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Management of BP during and after reperfusion treatment (eg, alteplase):",
"     </i>",
"     BP: Systolic &gt;230 mm Hg or diastolic &gt;121-140 mm Hg: 5 mg/hour; titrate by 2.5 mg/hour at 5-minute intervals (maximum dose: 15 mg/hour). If hypertension is refractory, consider other I.V. antihypertensives (eg, nitroprusside).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Substitution for oral therapy (approximate equivalents):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg every 8 hours oral, equivalent to 0.5 mg/hour I.V. infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg every 8 hours oral, equivalent to 1.2 mg/hour I.V. infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg every 8 hours oral, equivalent to 2.2 mg/hour I.V. infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Conversion to oral antihypertensive agent:",
"     </i>",
"     Initiate oral antihypertensive at the same time that I.V. nicardipine is discontinued, if transitioning to oral nicardipine, start oral nicardipine 1 hour prior to I.V. discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F201183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initiate at the low end of the dosage range. Specific guidelines for adjustment of nicardipine are not available, but careful monitoring is warranted and adjustment may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F201184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Per the manufacturer: Titrate dose beginning with 20 mg 3 times/day (immediate release) or 30 mg twice daily (sustained release capsule).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Specific guidelines for adjustment of nicardipine are not available, but careful monitoring is warranted and adjustment may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F201185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Per the manufacturer: Starting dose: 20 mg twice daily (immediate release) with titration. Refer to \"",
"     <b>",
"      Note",
"     </b>",
"     \" in adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Specific guidelines for adjustment of nicardipine are not available, but careful monitoring is warranted and adjustment may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F201152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 20 mg, 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, sustained release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardene&reg; SR: 30 mg, 45 mg, 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic dextrose solution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardene&reg; I.V.: 20 mg (200 mL); 40 mg (200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic sodium chloride solution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardene&reg; I.V.: 20 mg (200 mL); 40 mg (200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 2.5 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardene&reg; I.V.: 2.5 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F201138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule, injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F201156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: The total daily dose of immediate-release product may not automatically be equivalent to the daily sustained-release dose; use caution in converting. Do not chew or crush the sustained release formulation, swallow whole. Do not open or cut capsules.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vials must be diluted before use. Administer as a slow continuous infusion at a concentration of 0.1 mg/mL or 0.2 mg/mL. Concentrations of 0.5 mg/mL may be administered via a central line only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premixed bags: No further dilution needed. For single use only, discard any unused portion. Use only if solution is clear; the manufacturer recommends not to admix or run in the same line as other medications.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14472949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     25 mg in 250 mL (total volume) (concentration: 0.1 mg/mL)",
"     <b>",
"      or",
"     </b>",
"     25 mg in 50 mL (total volume) (concentration: 0.5 mg/mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     100",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"     <b>",
"      or",
"     </b>",
"     500",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F201222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W with KCl 40 mEq, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with sodium bicarbonate 5%;",
"     <b>",
"      variable stability (consult detailed reference):",
"     </b>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, aminophylline, aztreonam, butorphanol, calcium gluconate, cefazolin, chloramphenicol, cimetidine, clindamycin, diltiazem, dobutamine, dopamine, enalaprilat, epinephrine, erythromycin, esmolol, famotidine, fenoldopam, fentanyl, gentamicin, hydrocortisone sodium succinate, hydromorphone, labetalol, lidocaine, linezolid, lorazepam, magnesium, methylprednisolone sodium succinate, metronidazole, midazolam, milrinone, morphine, nafcillin, nesiritide, nitroglycerin, nitroprusside, norepinephrine, penicillin G potassium, piperacillin, potassium chloride, potassium phosphate, ranitidine, sodium acetate, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, vecuronium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ampicillin, ampicillin/sulbactam, cefepime, furosemide, micafungin, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftazidime, heparin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F201155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chronic stable angina (immediate-release product only); management of hypertension (immediate and sustained release products); parenteral only for short-term use when oral treatment is not feasible",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F201211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Congestive heart failure, control of blood pressure in acute ischemic stroke and spontaneous intracranial hemorrhage, postoperative hypertension associated with carotid endarterectomy, perioperative hypertension, prevention of migraine headaches, subarachnoid hemorrhage associated cerebral vasospasm",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F201224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       NiCARdipine may be confused with niacinamide, NIFEdipine, niMODipine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cardene&reg; may be confused with Cardizem&reg;, Cardura&reg;, codeine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cardene [U.S., Great Britain, Netherlands] may be confused with Cardem brand name for celiprolol [Spain]; Cardin brand name for simvastatin [Poland]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F201213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Cardiovascular: Flushing (6% to 10%), peripheral edema (dose related; 6% to 8%), hypotension (I.V. 6%), increased angina (dose related; 6%), palpitation (3% to 4%), tachycardia (1% to 4%), vasodilation (1% to 5%), chest pain (I.V. 1%), ECG abnormal (I.V. 1%), extrasystoles (I.V. 1%), hemopericardium (I.V. 1%), hypertension (I.V. 1%), orthostasis (1%), supraventricular tachycardia (I.V. 1%), syncope (1%), ventricular extrasystoles (I.V. 1%),  ventricular tachycardia (I.V. 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (6% to 15%), dizziness (1% to 7%), hypoesthesia (1%), intracranial hemorrhage (1%) pain (1%), somnolence (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (I.V. 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (2% to 5%), vomiting (I.V. 5%), dyspepsia (oral 2%), abdominal pain (I.V. 1%), dry mouth (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Polyuria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site pain (I.V. 1%), injection site reaction (I.V. 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (1% to 6%), myalgia (1%), paresthesia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, confusion, constipation, deep vein thrombophlebitis; ECG effects (AV block, inverted T wave, ST segment depression); gingival hyperplasia, hypertonia, hypophosphatemia, insomnia, malaise, nervousness, nocturia,  parotitis, thrombocytopenia, tinnitus, tremor",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F201159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nicardipine or any component of the formulation; advanced aortic stenosis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F201142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina/MI: Increased angina and/or MI has occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Avoid systemic hypotension in acute cerebral infarction or hemorrhage. Close monitoring of blood pressure and heart rate is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral edema: A common side effect is peripheral edema (dose-dependent); occurs within 2-3 weeks of starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with mild-to-moderate aortic stenosis; may reduce coronary perfusion resulting in ischemia. Use is contraindicated in patients with advanced aortic stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with HF. Use in patients with severe left ventricular dysfunction, particularly with concomitant beta-blockade, may experience worsened symptoms of HF due to mild negative inotropic effects of nicardipine. Titrate dosage slowly if utilizing I.V. nicardipine in patients with HF.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Consider lower starting dose and closely monitor response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Increase dose cautiously in patients with renal impairment since clearance of nicardipine is diminished in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Nicardipine should be initiated at the low end of the dosage range in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion sites: To minimize infusion site reactions, peripheral infusion sites (for I.V. therapy) should be changed every 12 hours; use of small peripheral veins should be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Abrupt withdrawal may cause rebound angina in patients with CAD.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F201209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (moderate), CYP2C9 (strong), CYP2D6 (moderate), CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F201147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of NiCARdipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F201175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Nicardipine average peak concentrations may be decreased if taken with food. Serum concentrations/toxicity of nicardipine may be increased by grapefruit juice. Management: Avoid grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Some herbal medications may worsen hypertension (eg, licorice); others may increase the antihypertensive effect of nicardipine (eg, shepherd's purse). Management: Avoid St John's wort. Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice, and yohimbe. Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F201149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F201162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Nicardipine has been used for the treatment of severe hypertension in pregnancy and pre-term labor. Nicardipine crosses the placenta; changes in fetal heart rate, neonatal hypotension and neonatal acidosis have been observed following maternal use (rare; based on limited data). Adverse effects reported in pregnant women are generally similar to those reported in non pregnant patients; however pulmonary edema has been observed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F201189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9933181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nicardipine is minimally excreted into breast milk. In one study, peak milk concentrations ranged from 1.9-18.8 mcg/mL following oral maternal doses of 40-150 mg/day. The estimated exposure to the breast-feeding infant was calculated to be 0.073% of the weight-adjusted maternal oral dose or 0.14% of the weight-adjusted maternal I.V. dose.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9601783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F201161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 12-hour",
"     </b>",
"     (Cardene SR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (60): $119.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (60): $227.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (NiCARdipine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $39.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $62.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cardene IV Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg/mL (10 mL): $281.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/200 mL 0.86% (200 mL): $114.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/200 mL 4.8% (200 mL): $114.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/200 mL 0.83% (200 mL): $228.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/200 mL 5% (200 mL): $228.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (NiCARdipine HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg/mL (10 mL): $33.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9933182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F201163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antagonil (DE);",
"     </li>",
"     <li>",
"      Barizin (HR);",
"     </li>",
"     <li>",
"      Blistra (ID);",
"     </li>",
"     <li>",
"      Cardene (IE, NL);",
"     </li>",
"     <li>",
"      Cardene SR (GB, NL);",
"     </li>",
"     <li>",
"      Cardepine (MY);",
"     </li>",
"     <li>",
"      Cardepine SR (MY);",
"     </li>",
"     <li>",
"      Cardibloc (SG);",
"     </li>",
"     <li>",
"      Cardipene (TH);",
"     </li>",
"     <li>",
"      Convertal (PE);",
"     </li>",
"     <li>",
"      Dacarel (PY, UY);",
"     </li>",
"     <li>",
"      Dafil (AR);",
"     </li>",
"     <li>",
"      Karden (AT);",
"     </li>",
"     <li>",
"      Lincil (HN);",
"     </li>",
"     <li>",
"      Loxen (FR);",
"     </li>",
"     <li>",
"      Nerdipina (ES, PT);",
"     </li>",
"     <li>",
"      Nicardal (IT);",
"     </li>",
"     <li>",
"      Nimicor (IT);",
"     </li>",
"     <li>",
"      Perdipina (IT);",
"     </li>",
"     <li>",
"      Perdipine (CL, ID, JP, KP, PH, TW);",
"     </li>",
"     <li>",
"      Perdipine LA (JP);",
"     </li>",
"     <li>",
"      Ridene (MX);",
"     </li>",
"     <li>",
"      Rydene (BE, LU);",
"     </li>",
"     <li>",
"      Vasonase (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F201141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F201158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: 0.5-2 hours; I.V.: 10 minutes; Hypotension: ~20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: &le;8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Immediate release capsules: &le;8 hours; Sustained release capsules: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: ~100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; CYP3A4 substrate (major); extensive first-pass effect (saturable)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 35%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral:  Immediate release: 30-120 minutes; Sustained release: 60-240 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (49% to 60% as metabolites); feces (43% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adams HP, del Zoppo G, Alberts MJ, et al, &ldquo;Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2007, 38(5):1655-1711. Available at file://stroke.ahajournals.org/cgi/reprint/STROKEAHA.107.181486",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/61/42969/abstract-text/17431204/pubmed\" id=\"17431204\" target=\"_blank\">",
"        17431204",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):1-157. Available at file://content.onlinejacc.org/cgi/reprint/50/7/e1",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/61/42969/abstract-text/17679616/pubmed\" id=\"17679616\" target=\"_blank\">",
"        17679616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baaske DM, DeMay JF, Latona CA, et al, &ldquo;Stability of Nicardipine Hydrochloride in Intravenous Solutions,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1996, 53(14):1701-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/61/42969/abstract-text/8827237/pubmed\" id=\"8827237\" target=\"_blank\">",
"        8827237",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartels PA, Hanff LM, Mathot RA, et al, &ldquo;Nicardipine in Pre-Eclamptic Patients: Placental Transfer and Disposition in Breast Milk,&rdquo;",
"      <i>",
"       BJOG",
"      </i>",
"      , 2007,114(2):230-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/61/42969/abstract-text/17166219/pubmed\" id=\"17166219\" target=\"_blank\">",
"        17166219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broderick J, Connolly S, Feldman E, et al, &ldquo;Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update:  A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2007, 38(6):2001-23. Available at  file://stroke.ahajournals.org/cgi/reprint/STROKEAHA.107.183689",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/61/42969/abstract-text/17478736/pubmed\" id=\"17478736\" target=\"_blank\">",
"        17478736",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/61/42969/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dorman T, Thompson DA, Breslow MJ, et al, &ldquo;Nicardipine versus Nitroprusside for Breakthrough Hypertension Following Carotid Endarterectomy,&rdquo;",
"      <i>",
"       J Clin Anesth",
"      </i>",
"      , 2001, 13(1):16-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/61/42969/abstract-text/11259889/pubmed\" id=\"11259889\" target=\"_blank\">",
"        11259889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erstad BL and Barletta JF, &ldquo;Treatment of Hypertension in the Perioperative Patient,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(1):66-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/61/42969/abstract-text/10669188/pubmed\" id=\"10669188\" target=\"_blank\">",
"        10669188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/61/42969/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flynn JT, Mottes TA, Brophy PD, et al, &ldquo;Intravenous Nicardipine for Treatment of Severe Hypertension in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 139(1):38-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/61/42969/abstract-text/11445792/pubmed\" id=\"11445792\" target=\"_blank\">",
"        11445792",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jauch EC, Cucchiara B, Adeoye O, et al, &ldquo;Part 11: Adult Stroke: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):818-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/61/42969/abstract-text/20956227/pubmed\" id=\"20956227\" target=\"_blank\">",
"        20956227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marik PE and Varon J, &ldquo;Hypertensive Crises: Challenges and Management,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2007, 131(6);1949-62. Available at file://chestjournal.chestpubs.org/content/131/6/1949.full.pdf+html",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/61/42969/abstract-text/17565029/pubmed\" id=\"17565029\" target=\"_blank\">",
"        17565029",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/61/42969/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nij Bijvank SW and Duvekot JJ, \"Nicardipine for the Treatment of Severe Hypertension in Pregnancy: A Review of the Literature,\"",
"      <i>",
"       Obstet Gynecol Surv",
"      </i>",
"      , 2010, 65(5):341-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/61/42969/abstract-text/20591204/pubmed\" id=\"20591204\" target=\"_blank\">",
"        20591204",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Randomized Double-Blind Comparison of a Calcium Antagonist and a Diuretic in Elderly Hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 1999, 34(5):1129-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/61/42969/abstract-text/10567194/pubmed\" id=\"10567194\" target=\"_blank\">",
"        10567194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steele RM, Schuna AA, and Schreiber RT, &ldquo;Calcium Antagonist-Induced Gingival Hyperplasia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1994, 120(8):663-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/61/42969/abstract-text/8135450/pubmed\" id=\"8135450\" target=\"_blank\">",
"        8135450",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wallin JD, Fletcher E, Ram CV, et al, &ldquo;Intravenous Nicardipine for the Treatment of Severe Hypertension. A Double-Blind, Placebo-Controlled Multicenter Trial,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1989, 149(12):2662-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/61/42969/abstract-text/2688586/pubmed\" id=\"2688586\" target=\"_blank\">",
"        2688586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9697 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B09A38F648-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_61_42969=[""].join("\n");
var outline_f41_61_42969=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201178\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201215\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201182\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201183\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201184\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201185\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201152\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201138\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201156\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472949\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472950\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201222\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201155\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201211\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201224\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201213\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201159\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201142\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201209\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201147\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201175\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201149\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201162\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201189\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9933181\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9601783\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201161\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9933182\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201163\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201141\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201158\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9697\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9697|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/10/12453?source=related_link\">",
"      Nicardipine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/38/32361?source=related_link\">",
"      Nicardipine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_61_42970="Dermatitis herpetiformis knee";
var content_f41_61_42970=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86749%7EDERM%2F86750%7EDERM%2F86751%7EDERM%2F86752%7EDERM%2F86768%7EDERM%2F78315%7EDERM%2F86769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86749%7EDERM%2F86750%7EDERM%2F86751%7EDERM%2F86752%7EDERM%2F86768%7EDERM%2F78315%7EDERM%2F86769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatitis herpetiformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules and vesicles are present on the knee.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dermatitis herpetiformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple excoriated erythematous papules are present on the buttocks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dermatitis herpetiformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules and vesicles are present on the knees.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dermatitis herpetiformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 438px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A few vesicles are present near the elbow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatitis herpetiformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple inflammatory papules and vesicles are present near the elbow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Florell, MD, Department of Dermatology, University of Utah.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dermatitis herpetiformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vesicles, bullae, erosions, and crusts on elbow skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatitis herpetiformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple excoriated papules and crusts are present near the elbow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_61_42970=[""].join("\n");
var outline_f41_61_42970=null;
var title_f41_61_42971="Chronic pain synd antineo";
var content_f41_61_42971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chronic pain syndromes directly related to antineoplastic treatments",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Chronic pain syndromes associated with chemotherapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Painful peripheral neuropathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Raynaud's syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bony complications of long-term glucocorticoid treatment, including avascular (aseptic) necrosis of femoral or humeral head, and vertebral compression fractures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Chronic pain syndromes associated with hormonal therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic gynecomastia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Osteoporotic compression fractures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Chronic pain syndromes associated with surgery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Post-mastectomy pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Post-radical neck dissection pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Post-thoracotomy pain, frozen shoulder",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Post-surgery pelvic floor pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stump pain, phantom limb pain post amputation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Post-mastectomy phantom breast pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Chronic post-radiation pain syndromes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Radiation-induced late brachial plexopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic radiation myelopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic radiation enteritis and proctitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lymphedema pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Burning perineum syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Osteoradionecrosis",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_61_42971=[""].join("\n");
var outline_f41_61_42971=null;
var title_f41_61_42972="Relative potency glucocorticoids";
var content_f41_61_42972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F64138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F64138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of representative glucocorticoid preparations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Approximate equivalent dose*",
"        <br/>",
"        (mg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relative anti-inflammatory activity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relative mineralocorticoid activity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration of action",
"        <br/>",
"        (hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cortisol",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        8 to 12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cortisone acetate",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        8 to 12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocortisone",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        8 to 12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prednisone",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        12 to 36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prednisolone",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        12 to 36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methylprednisolone",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        12 to 36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triamcinolone",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        12 to 36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fludrocortisone",
"        <br/>",
"        (see NOTE)",
"       </td>",
"       <td>",
"        &Delta;",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        12 to 36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dexamethasone",
"       </td>",
"       <td>",
"        0.75",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        36 to 72",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Prednisone and prednisolone are potent glucocorticoids and weak mineralocorticoids. Methylprednisolone and dexamethasone have no mineralocorticoid effect.",
"    <br/>",
"    NOTE: Glucocorticoid doses which provide a mineralocorticoid effect that is approximately equivalent to 0.1 mg fludrocortisone are: prednisone or prednisolone 50 mg, or hydrocortisone 20 mg.",
"    <div class=\"footnotes\">",
"     * Equivalent dose shown is for oral or IV administration. Relative potency for intra-articular or intramuscular administration may vary considerably.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Data for cortisol, endogenous corticosteroid hormone, are included for comparison with synthetic preparations listed.",
"     <br/>",
"     &Delta; Fludricortisone is not used for an anti-inflammatory effect.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: The Pharmacological Basis of Therapeutics, 11th ed, Brunton LL, Lazo JS, Parker KL (Eds), McGraw Hill, NY. p.1587. Copyright &copy; 2006",
"      </li>",
"      <li>",
"       Donohoue PA. The adrenal gland and its disorders. Kappy MS, Allen DB, Geffner ME (Eds), Charles C Thomas, Springfield, IL. p.403. Copyright &copy; 2005 Charles C Thomas, Publisher, Ltd.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_61_42972=[""].join("\n");
var outline_f41_61_42972=null;
var title_f41_61_42973="Linear morphea - arm";
var content_f41_61_42973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Linear morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 76px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sclerotic, hyperpigmented, linear plaques are present on the arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_61_42973=[""].join("\n");
var outline_f41_61_42973=null;
var title_f41_61_42974="X-linked adrenoleukodystrophy A";
var content_f41_61_42974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70311%7EPEDS%2F80404%7EPEDS%2F59029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=17\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70311%7EPEDS%2F80404%7EPEDS%2F59029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=17\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    X-linked adrenoleukodystrophy (X-ALD) phenotypes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Phenotypes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total ALD, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptoms/ signs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age at present- ation (years)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mis- diagnosed as",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diag- nostic test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Follow- up tests",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recom- mended therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asymptomatic (MRI normal)",
"       </td>",
"       <td>",
"        Increasing",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        0 to &ge;10",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        <p>",
"         VLCFA in relatives of X-ALD patients",
"        </p>",
"        <p>",
"         Confirm with DNA",
"        </p>",
"       </td>",
"       <td>",
"        Monitor MRI and adrenal function; family screening",
"       </td>",
"       <td>",
"        Lorenzo's oil, adrenal HRT if indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asymptomatic (MRI abnormal)",
"       </td>",
"       <td>",
"        Increasing",
"       </td>",
"       <td>",
"        None (cognition normal)",
"       </td>",
"       <td>",
"        2 to &ge;10",
"       </td>",
"       <td>",
"        Other white matter disorders",
"       </td>",
"       <td>",
"        <p>",
"         VLCFA, brain MRI",
"        </p>",
"        <p>",
"         Confirm with DNA",
"        </p>",
"       </td>",
"       <td>",
"        Neurological and neuro- psychological testing, adrenal function",
"       </td>",
"       <td>",
"        HSCT, adrenal HRT if indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Addison disease only (MRI normal)",
"       </td>",
"       <td>",
"        20 (decreases with age)",
"       </td>",
"       <td>",
"        Primary adrenocortical insufficiency, normal neurology, MRI normal",
"       </td>",
"       <td>",
"        0 to &ge;10",
"       </td>",
"       <td>",
"        Other causes of Addison disease",
"       </td>",
"       <td>",
"        <p>",
"         VLCFA",
"        </p>",
"        <p>",
"         Confirm with DNA",
"        </p>",
"       </td>",
"       <td>",
"        Monitor MRI, neurological and neuro- psychological testing",
"       </td>",
"       <td>",
"        Lorenzo's oil, adrenal HRT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Addison disease only (MRI abnormal)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Primary adrenocortical insufficiency",
"       </td>",
"       <td>",
"        0 to &ge;10",
"       </td>",
"       <td>",
"        Other causes of Addison disease",
"       </td>",
"       <td>",
"        <p>",
"         VLCFA, brain MRI",
"        </p>",
"        <p>",
"         Confirm with DNA",
"        </p>",
"       </td>",
"       <td>",
"        Neurological and neuro- psychological testing, MRI",
"       </td>",
"       <td>",
"        HSCT, adrenal HRT if indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Cerebral (mild) without AMN*",
"       </td>",
"       <td rowspan=\"3\">",
"        45",
"       </td>",
"       <td rowspan=\"3\">",
"        Behavior changes, school failure, dementia, audiovisual",
"       </td>",
"       <td>",
"        3-10 (common)",
"       </td>",
"       <td rowspan=\"3\">",
"        ADHD, psychological disorder, Asperger syndrome, autism",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         VLCFA, brain MRI",
"        </p>",
"        <p>",
"         Confirm with DNA",
"        </p>",
"       </td>",
"       <td rowspan=\"3\">",
"        Neurological and neuro- psychological testing, family screening, adrenal function",
"       </td>",
"       <td rowspan=\"3\">",
"        HSCT, adrenal HRT if indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11-21 (inter- mediate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        21 (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerebral (severe) without AMN*",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        Dementia, psychoses, paralysis, epilepsy, loss of vision, loss of speech, bulbar palsy",
"       </td>",
"       <td>",
"        5 to adulthood",
"       </td>",
"       <td>",
"        Other neuro- degenerative diseases, brain tumor, psychosis, epilepsy",
"       </td>",
"       <td>",
"        <p>",
"         VLCFA, brain MRI",
"        </p>",
"        <p>",
"         Confirm with DNA",
"        </p>",
"       </td>",
"       <td>",
"        Adrenal function, neurological and neuro- psychological testing, family screening",
"       </td>",
"       <td>",
"        Adrenal HRT if indicated, general support",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Percentages listed above vary by age group, as the asymptomatic and Addison disease groups decline with age while the ALD and AMN groups increase.",
"    <div class=\"footnotes\">",
"     ADHD: attention-deficit/hyperactivity disorder; ALS: amyotrophic lateral sclerosis; DNA: ABCD1 mutation analysis; AMN: adrenomyeloneuropathy; EEG: electroencephalogram; HRT: hormone replacement therapy; HSCT: hematopoietic stem cell transplant; MRI: magnetic resonance imaging; MTS: magnetization transfer MRI cervical cord; SSEP: somatosensory evoked potential; VLCFA: very long chain fatty acids assay in plasma.",
"     <br>",
"      * For a description of the distinction between the mild and severe cerebral forms, see: Peters C, Charnas LR, Tan Y, et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood 2004;104:881.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moser HW, Raymond GV, Dubey P. Adrenoleukodystrophy: new approaches to a neurodegenerative disease. JAMA 2005; 294:3131. Copyright &copy; 2005 American Medical Association. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    X-linked adrenoleukodystrophy (X-ALD) phenotypes, continued",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Phenotypes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total ALD, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptoms/ signs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age at present- ation, y",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mis- diagnosed as",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diag- nostic test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Follow-up tests",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recom- mended therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\" rowspan=\"1\">",
"        Males, continued",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pure AMN&bull;",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        Paraparesis, sphincter disturbances, sensory changes, incoordination, pain, impotence",
"       </td>",
"       <td>",
"        28 (SD,9)",
"       </td>",
"       <td>",
"        Multiple sclerosis, progressive spastic paraparesis, cervical spondylosis, osteoarthritis, back injury, ALS, \"triple A syndrome\"",
"       </td>",
"       <td>",
"        <p>",
"         VLCFA",
"        </p>",
"        <p>",
"         Confirm with DNA",
"        </p>",
"       </td>",
"       <td>",
"        Brain MRI, adrenal function, MTS, SSEP, family screening",
"       </td>",
"       <td>",
"        Adrenal HRT if indicated, possibly Lorenzo's oil,&Delta; physical therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerebral AMN&bull;",
"       </td>",
"       <td>",
"        15 (increases with age)",
"       </td>",
"       <td>",
"        Like pure AMN plus dementia, behavioral disturbances, psychosis, epilepsy, aphasia, visual loss, bulbar palsy",
"       </td>",
"       <td>",
"        28 (SD, 9)",
"       </td>",
"       <td>",
"        Other causes, dementia, other neuro- degenerative diseases, brain tumor, schizophrenia, Alzheimer disease, cerebro- vascular disease, epilepsy, alcoholism, drug dependency",
"       </td>",
"       <td>",
"        <p>",
"         VLCFA, brain MRI",
"        </p>",
"        <p>",
"         Confirm with DNA",
"        </p>",
"       </td>",
"       <td>",
"        As in pure AMN plus neurological and neuro- psychological testing, EEG, psychiatry, family screening",
"       </td>",
"       <td>",
"        Adrenal HRT if indicated, general support, possibly HSCT&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerebellar",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        Ataxia, brainstem",
"       </td>",
"       <td>",
"        Child- hood; adole- scence",
"       </td>",
"       <td>",
"        Olivoponto- cerebellar degeneration",
"       </td>",
"       <td>",
"        <p>",
"         VLCFA, brain MRI",
"        </p>",
"        <p>",
"         Confirm with DNA",
"        </p>",
"       </td>",
"       <td>",
"        Adrenal function, neurological testing, family screening",
"       </td>",
"       <td>",
"        Adrenal HRT if indicated, physical therapy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Percentages listed above vary by age group, as the asymptomatic and Addison disease groups decline with age while the ALD and AMN groups increase.",
"    <div class=\"footnotes\">",
"     ADHD: attention-deficit/hyperactivity disorder; ALS: amyotrophic lateral sclerosis; DNA: ABCD1 mutation analysis; AMN: adrenomyeloneuropathy; EEG: electroencephalogram; HRT: hormone replacement therapy; HSCT: hematopoietic stem cell transplant; MRI: magnetic resonance imaging; MTS: magnetization transfer MRI cervical cord; SSEP: somatosensory evoked potential; VLCFA: very long chain fatty acids assay in plasma.",
"     <br>",
"      &bull; See text for distinction between pure and cerebral AMN.",
"      <br>",
"       &Delta; Placebo-controlled trial in progress.",
"       <br>",
"        &loz; HSCT being considered for mild cerebral AMN.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moser HW, Raymond GV, Dubey P. Adrenoleukodustrophy: new approaches to a Neurodegenerative Disease. JAMA 2005; 294:3131. Copyright &copy; 2005 American Medical Association. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    X-linked adrenoleukodystrophy (X-ALD) phenotypes, continued",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Phenotypes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total ALD, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptoms/ signs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age at present- ation, y",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mis- diagnosed as",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diag- nostic test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Follow-up tests",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recom- mended therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\" rowspan=\"1\">",
"        Females Heterozygous for ALD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asymptomatic (normal neurology)",
"       </td>",
"       <td>",
"        50 (estimated)",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Any age",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        DNA (VLCFA)&sect;",
"       </td>",
"       <td>",
"        Neurological examination and adrenal function, monitor MRI, family screening",
"       </td>",
"       <td>",
"        Genetic counseling, general support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Heterozygotes (symptoms or neurological abnormalities)",
"       </td>",
"       <td>",
"        50 (estimated)",
"       </td>",
"       <td>",
"        Paraparesis, sphincter disturbances, leg pain, sensory disturbances, incoordination, fatigue",
"       </td>",
"       <td>",
"        Rare in women younger than 30 y",
"       </td>",
"       <td>",
"        Multiple sclerosis, spastic paraparesis, peripheral neuropathy, cervical spondylosis, back injury, arthritis, herniated disk",
"       </td>",
"       <td>",
"        DNA (VLCFA)&sect;",
"       </td>",
"       <td>",
"        Adrenal function, MTS, SSEP, family screening",
"       </td>",
"       <td>",
"        Genetic counseling, physical therapy, adrenal HRT if indicated, possibly Lorenzo's oil,&Delta; general support",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADHD: attention-deficit/hyperactivity disorder; ALS: amyotrophic lateral sclerosis; DNA: ABCD1 mutation analysis; AMN: adrenomyeloneuropathy; EEG: electroencephalogram; HRT: hormone replacement therapy; HSCT: hematopoietic stem cell transplant; MRI: magnetic resonance imaging; MTS: magnetization transfer MRI cervical cord; SSEP: somatosensory evoked potential; VLCFA: very long chain fatty acids assay in plasma.",
"     <br>",
"      &Delta; Placebo-controlled trial in progress.",
"      <br>",
"       &sect; False-negative test results can occur.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moser HW, Raymond GV, Dubey P. Adrenoleukodustrophy: new approaches to a Neurodegenerative Disease. JAMA 2005; 294:3131. Copyright &copy; 2005 American Medical Association. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_61_42974=[""].join("\n");
var outline_f41_61_42974=null;
var title_f41_61_42975="Anterior drawer test2";
var content_f41_61_42975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior drawer test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anterior drawer test is used to assess the integrity of the anterior cruciate ligament. With the knee flexed to 90&ordm; and the foot stabilized, the proximal tibia is grasped firmly with both hands, and the tibia is forcibly pulled anteriorly, noting any pain, laxity, or abnormal movement compared with the opposite side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_61_42975=[""].join("\n");
var outline_f41_61_42975=null;
